

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Pirfenidone for the prevention of radiation-induced lung injury in patients with locally advanced esophageal squamous cell carcinoma: A randomized controlled trial protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-060619
Article Type:	Protocol
Date Submitted by the Author:	04-Jan-2022
Complete List of Authors:	Chen, Cheng; Fujian Medical University Union Hospital, Department of Radiation Oncology Zeng, Bangwei; Fujian Medical University Union Hospital, Nosocomial Infection Control Branch Xue, Dan; Fujian Medical University Union Hospital, Pulmonary Department Cao, Rongxiang; Fujian Medical University Union Hospital, Pulmonary Department Liao, Siqin; Fujian Medical University Union Hospital, Department of PET/CT Center Yang, Yong; Fujian Medical University Union Hospital, Department of Radiation Oncology Li, Zhihua; No.1 Hospital of Longhai, Department of Oncology Department Kang, Mingqiang; Fujian Medical University Union Hospital, Department of Thoracic Surgery Chen, Chun; Fujian Medical University Union Hospital, Department of Thoracic Surgery Xu, Benhua; Fujian Medical University Union Hospital, Department of Radiation Oncology
Keywords:	Adult oncology < ONCOLOGY, Radiation oncology < RADIOLOGY & IMAGING, Adult radiotherapy < RADIOTHERAPY, Radiation oncology < RADIOTHERAPY

SCHOLARONE™  
Manuscripts

1  
2  
3 **Pirfenidone for the prevention of radiation-induced lung injury in patients with**  
4 **locally advanced esophageal squamous cell carcinoma: A randomized controlled**  
5 **trial protocol**  
6  
7  
8  
9

10  
11  
12 Cheng Chen<sup>1, 4, 5</sup>, Bangwei Zeng<sup>2</sup>, Dan Xue<sup>3</sup>, Rongxiang Cao<sup>3</sup>, Siqin Liao<sup>7</sup>, Yong  
13 Yang<sup>1</sup>, Zhihua Li<sup>9</sup>, Mingqiang Kang<sup>8</sup>, Chun Chen<sup>8</sup>, Benhua Xu<sup>1, 4, 5, 6\*</sup>  
14  
15  
16

17  
18  
19 <sup>1</sup>Department of Radiation Oncology, Fujian Medical University Union Hospital,  
20 Fuzhou 350000, China  
21  
22

23  
24 <sup>2</sup>Nosocomial Infection Control Branch, Fujian Medical University Union Hospital,  
25 Fuzhou 350000, China  
26  
27

28  
29 <sup>3</sup>Pulmonary Department, Fujian Medical University Union Hospital, Fuzhou 350000,  
30 China  
31  
32

33  
34 <sup>4</sup>College of Medical Technology and Engineering, Fujian Medical University, Fuzhou  
35 350000, China  
36  
37

38  
39 <sup>5</sup>Union Clinical Medical College, Fujian Medical University, Fuzhou 350000, China

40  
41 <sup>6</sup>School of Clinical Medicine, Fujian Medical University, Fuzhou 350000, China

42  
43 <sup>7</sup>Department of PET/CT Center, Fujian Medical University Union Hospital, Fuzhou  
44 350000, China  
45  
46

47  
48 <sup>8</sup>Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou  
49 350000, China  
50

51  
52 <sup>9</sup>Department of Oncology Department, No.1 Hospital of Longhai, Zhangzhou 363199,  
53 China  
54  
55

56  
57  
58 **\*Corresponding author:**  
59  
60

1  
2  
3 Benhua Xu  
4

5 Department of Radiation Oncology, Fujian Medical University Union Hospital,  
6

7  
8 Fuzhou 350000, China  
9

10 College of Medical Technology and Engineering, Fujian Medical University, Fuzhou  
11

12 350000, China  
13

14 Union Clinical Medical College, Fujian Medical University, Fuzhou 350000, China  
15

16 School of Clinical Medicine, Fujian Medical University, Fuzhou 350000, China  
17

18  
19 Tel: +86-13365910602  
20

21  
22 E-mail: benhuaxu@163.com  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Introduction:** Radiation-induced lung injury (RILI) is among the most clinically-challenging toxicities and dose-limiting factors during/after thoracic radiation therapy for esophageal squamous cell carcinoma (ESCC). With limited effective protective drugs against RILI, the main strategy to reduce its likelihood is strict adherence to dose-volume constraints of normal lung. RILI can manifest as acute radiation pneumonitis of cellular injury, cytokine release, and cytokine recruitment of inflammatory infiltrate, and the ensuing chronic radiation pulmonary fibrosis. Pirfenidone inhibits inflammatory cytokines, scavenges free radicals, and reduces hydroxyproline and collagen formation. Hence, pirfenidone appears to be promising for RILI prevention. This study aims to evaluate the efficacy and safety of pirfenidone in preventing RILI in patients with locally advanced ESCC receiving chemoradiotherapy.

**Methods and analysis:** This study has been designed as a randomized, placebo-controlled, double-blind, single-center phase 2 trial and will explore whether the addition of pirfenidone during concurrent chemoradiation therapy (CCRT) will prevent RILI in patients with locally advanced ESCC unsuitable for surgery. Eligible participants will be randomized 1:1 to pirfenidone or placebo. The primary endpoint is the incidence of grade  $\geq 2$  RILI. The secondary endpoints include the incidence of any grade RILI, the time to the occurrence of RILI, the changes in pulmonary function after CCRT, the completion rate of CCRT, disease-free survival (DFS), and overall survival (OS). The follow-up will be 1 year. If the results meet the primary endpoint of this trial, a phase 3 multicenter trial with larger sample size will be needed to conclusively demonstrate the benefits of pirfenidone for preventing RILI.

## Ethics and dissemination

1  
2  
3 Ethics approval has been obtained from the Ethics Committee of Fujian Union  
4 Hospital (No. 2021YF001-02). The findings of the trial will be disseminated through  
5  
6 peer-reviewed journals, national and international conference presentations.  
7  
8  
9

10  
11  
12 **Trial registration number:** ChiCTR2100043032; Pre-results  
13  
14

### 15 16 17 **Strengths and limitations of this study**

- 18  
19 ● This is the first randomized controlled trial to explore the efficacy and safety of  
20  
21 pirfenidone in preventing RILI.  
22
- 23  
24 ● It is a double-blind trial that neither patients nor physicians will be masked to  
25  
26 treatment allocation.  
27
- 28  
29 ● It is a phase 2 trial performed at a single center.  
30
- 31  
32 ● The dosage of radiation was inconsistent, with unresectable patients receiving 50  
33  
34 Gy to 60 Gy, and with downstaging patients receiving 40 Gy due to further  
35  
36 conversion to surgical resection.  
37

38  
39  
40 **Key words:** pirfenidone; radiation-induced lung injury; prevention; esophageal  
41  
42 squamous cell carcinoma; concurrent chemoradiation therapy; randomized controlled  
43  
44 trial.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Introduction

Esophageal cancer ranks the eighth most common cause of cancer in the world. Among the 477,900 new patients reported globally per year, nearly a half occur in China, and 90% of them are esophageal squamous cell carcinoma (ESCC).<sup>1</sup> The standard of care for unresectable locally advanced ESCC remains definitive concurrent chemoradiation therapy, with a 3-year OS rate of 30%-37%.<sup>2-5</sup> Because the lungs often lay in the path of the treatment beams, radiation-induced lung injury (RILI) is one of the most common complications and potentially dose-limiting toxicities of radiotherapy for esophageal cancer, with an incidence of about 10.7%-35.14%.<sup>6-11</sup> Furthermore, RILI during radiation can delay or even interrupt radiotherapy, resulting in poor local disease control, increased financial burden, and even death.

Although advanced radiotherapy technologies such as intensity-modulated radiation therapy (IMRT) are superior to traditional 2D and 3D conformal radiation therapy regarding dosimetry and organ protection,<sup>10 12</sup> many patients still develop varying degrees of RILI.<sup>13</sup> In clinical practice, there is no specific treatment for RILI except oxygen inhalation, glucocorticoids administration, and application of antibiotics when necessary. Therefore, preventing RILI is of greater clinical significance than treating it. Although amifostine has been approved by the US Food & Drug Administration (FDA) for radiotherapy protection, it did not show significant efficacy in protecting against RILI during treatments for esophageal cancer.<sup>14 15</sup> Moreover, its clinical application is limited owing to the high price and high rates of side effects. Therefore, there are few effective protective strategies against RILI during radiation therapy for patients with ESCC.

Pirfenidone is an active small-molecule oral drug that can inhibit the

1  
2  
3 overexpression of transforming growth factor (TGF)- $\beta$ 1 and meanwhile reduce the  
4 secretion of platelet-derived growth factor (PDGF) and fibroblast growth factor  
5 (FGF), thereby inhibiting the biological activity of fibroblasts.<sup>16-18</sup> Pharmacodynamic  
6 experiments showed that pirfenidone had satisfying effects against lung inflammation  
7 and fibrosis.<sup>19-22</sup> The FDA approved pirfenidone in 2014 to treat idiopathic pulmonary  
8 fibrosis (IPF),<sup>23 24</sup> which shares some common pathological processes with RILI.<sup>25 26</sup>  
9  
10 A study in mice showed that pirfenidone could attenuate RILI.<sup>27</sup> A phase 2 trial is  
11 under recruitment and aims to confirm the efficacy of pirfenidone for the treatment of  
12 RILI (ClinicalTrials.gov NCT03902509) rather than for its prevention.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

23  
24 There are no published clinical data to assess the preventive role of pirfenidone  
25 against RILI. Therefore, this randomized, placebo-controlled, double-blind,  
26 single-center, phase 2 trial was designed to examine whether pirfenidone can reduce  
27 the incidence of RILI in patients with locally advanced ESCC receiving CCRT.  
28  
29  
30  
31  
32  
33  
34

## 35 **Methods**

### 36 ***Study design and participants***

37  
38 This study is a randomized, placebo-controlled, double-blind, single-center, phase  
39 2 clinical trial to examine the preventive role of pirfenidone for RILI in patients with  
40 unresectable locally advanced ESCC undergoing CCRT. The participants will be  
41 randomized 1:1 to the pirfenidone or control groups. Figure 1 presents the overview  
42 of the study flowchart.  
43  
44  
45  
46  
47  
48  
49

50  
51 The full inclusion, exclusion, and withdrawal criteria are listed in Table 1.  
52

53  
54 All eligible patients must sign a written informed consent and be willing to  
55 participate in and complete the study and follow-up.  
56  
57

### 58 ***Pre-treatment assessment and screening***



1  
2  
3 Each patient must complete the following examinations and counseling within 1  
4  
5 or 2 weeks before entering the trial:  
6  
7

- 8 1) Detailed medical history review.
- 9  
10 2) Physical examination (height, weight, vital signs, and Eastern Cooperative  
11  
12 Oncology Group (ECOG) performance status).
- 13  
14 3) Blood tests, including complete blood counts (CBC), biochemical profiles,  
15  
16 coagulation function, hepatitis B virus (HBV) screening and HBV DNA (for  
17  
18 HBsAg-positive patients), esophageal cancer-related tumor markers of  
19  
20 carcinoembryonic antigen (CEA), cancer antigen (CA) 199, CA125, CA153,  
21  
22 neuron-specific enolase (NSE), squamous cell carcinoma antigen (SCC), soluble  
23  
24 fragment of cytokeratin 19 (Cyfra21-1), and  $\alpha$ -fetoprotein (AFP).  
25  
26  
27 4) Cardiopulmonary function, including electrocardiogram, ultrasonic cardiogram,  
28  
29 and pulmonary function.  
30  
31  
32 5) Upper gastrointestinal endoscopy and biopsy.
- 33  
34 6) Imaging, including chest/abdominal computed tomography (CT) with intravenous  
35  
36 contrast, upper gastrointestinal swallowed meglumine diatrizoate contrast, pelvic CT  
37  
38 with contrast as clinically indicated, and FDG-PET/CT evaluation if the patient agrees,  
39  
40 leading to more accurate staging.  
41  
42  
43 7) Nutritional assessment and counseling.
- 44  
45  
46 8) Smoking cessation advice.
- 47  
48

### 49 ***Radiotherapy***

50  
51 The target contour principle is as follows. Gross tumor volume (GTV) should  
52  
53 include the primary tumor (GTVp) and enlarged regional lymph nodes (GTVn) by the  
54  
55 planning scan and other diagnostic imaging examinations. Elective node irradiation  
56  
57 (ENI) is used for clinical target volume (CTV) delineation. CTV of GTVp is defined  
58  
59  
60

1  
2  
3 as the primary tumor plus a 3-cm expansion superiorly and inferiorly along the length  
4 of the esophagus and a 0.5-1-cm radial expansion including the para-esophageal  
5 lymph nodes. CTV of GTVn should cover all involved and high-risk lymphatic  
6 drainage regions such as the supraclavicular for the super-thoracic and  
7 middle-thoracic sections.<sup>28</sup> Planning target volume (PTV) for GTV and CTV shall be  
8 created by expanding with a uniform margin of 0.5 cm separately.  
9

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
Bilateral lungs, heart, spinal cord, stomach, and liver are identified as organs at risk (OAR) and should be limited as follows: 1) lungs:  $\leq 28\%$ - $30\%$  of irradiated bilateral lung volume exceeding 20 Gy (V20), V5  $\leq 60\%$ , and mean lung dose (MLD)  $< 15$  Gy; 2) heart: V40  $< 30\%$ , V40  $\leq 30\%$ , and mean dose  $\leq 30$  Gy; 3) spinal cord: maximal dose (Dmax)  $\leq 45$  Gy; 4) stomach: V40  $\leq 40\%$  and Dmax  $\leq 55$ - $60$  Gy; and 5) liver: V30  $\leq 40\%$  and mean dose  $< 25$  Gy.

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
The prescribed dose to PTV-CTV and PTV-GTV are 50.4 Gy/1.8 Gy/28 fractions and 60 Gy/1.8 Gy/33 fractions, respectively. If the target area is large and OAR cannot be achieved, only PTV-GTV irradiation or PTV-CTV irradiation can be performed as decided by the treating radiotherapist. The prescription dose has to cover at least 95% of the PTV. Either volumetric-modulated arc therapy (VMAT) or IMRT is recommended for irradiation. Resectability will be re-assessed by a multidisciplinary tumor board at irradiation to 41.4 Gy for patients unsuitable for surgery at diagnosis. If possible for surgical resection, then radiation therapy will be terminated and the operation will perform after 4-8 weeks after termination of radiation.

### ***Chemotherapy***

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
The participants receive docetaxel 60 mg/m<sup>2</sup> intravenously on day 1 and cisplatin 30 mg/m<sup>2</sup> intravenously on days 1 and 2 (DP regimen) for two cycles. Polyethylene

glycol recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) is recommended for prevention of neutropenia during CCRT. Dose modification should be based on the preceding cycle CBC and biochemical markers. The chemotherapy can be continued if 1) absolute neutrophil count (ANC)  $\geq 1.5 \times 10^9/L$ , 2) platelet count  $\geq 100 \times 10^9/L$ , 3) alanine transaminase (ALT), aspartate transaminase (AST), and total bilirubin are CTC grade  $< 2$ , and 4) non-hematological toxicity (except for hair loss) returns to grade 1 or baseline level. The doses of both drugs should be decreased by 20% if any grade 3 or higher toxicities are observed. If grade 3 or 4 radiation pneumonitis occurs, radiotherapy and concurrent chemotherapy are terminated.

### ***Randomization and intervention***

The participants will be randomized 1:1 to the pirfenidone or control groups using a random number table and stratified according to the reasons whether they cannot tolerate surgery or the tumor cannot be removed surgically. Both the participants and the doctors are masked from grouping. Both pirfenidone and placebo capsules are provided by Beijing Continent Pharmaceutical Co., Ltd. The appearance, smell, taste, and properties of the placebo are the same as the study drug. Each capsule contains 100 mg of drug/placebo. In the first week, the dosage is 200 mg/time, 3 times/day. In the second week, the dosage is increased to 300 mg/time, 3 times/day. In weeks 3-12, the dosage is increased to 400 mg/time, 3 times/day. The pirfenidone treatment starts on the day when radiotherapy starts and lasts for 12 weeks. The capsules are taken during or after meals as gastrointestinal reactions are the most common adverse effects of pirfenidone. Photosensitivity is another common adverse event. External use of sunscreen and avoiding the sun during medication can effectively reduce the incidence and severity of photosensitivity. If the adverse events still occur or cannot be tolerated even after the dose is reduced, the drug can be

1  
2  
3 temporarily discontinued for 1-2 weeks until the participant tolerates the symptoms.  
4  
5 Once the adverse events recover or can be tolerated, the participant can retake  
6  
7 pirfenidone. The physician can decide whether to stop the drug according to the  
8  
9 situation. The pirfenidone treatment should be permanently discontinued if severe  
10  
11 adverse events occur, including liver dysfunction, jaundice, severe hypersensitivity,  
12  
13 and photosensitivity.  
14  
15

### 16 17 ***Concomitant medication***

18  
19 Drugs that may prevent or treat fibrosis are forbidden, such as amifostine and  
20  
21 thalidomide. The participants should avoid the concurrent use of drugs that increase  
22  
23 the adverse reactions of pirfenidone, including ciprofloxacin, amiodarone, and  
24  
25 propafenone. The participants should also avoid the concurrently receive of that can  
26  
27 reduce the efficacy of pirfenidone, such as omeprazole and rifampin.  
28  
29

### 30 31 ***Endpoints***

32  
33 The primary endpoint is the incidence of grade 2 or higher RILI in participants in  
34  
35 the full analysis set (FAS) and per-protocol set (PPS). RILI will be evaluated  
36  
37 according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0  
38  
39 within 1 year. The secondary endpoints include the incidence of RILI of any grade,  
40  
41 the time to the occurrence of RILI, changes in pulmonary function after radiotherapy,  
42  
43 the completion rate of CCRT, disease-free survival (DFS), and overall survival (OS).  
44  
45

### 46 47 ***Follow-up***

- 48  
49 1. During intervention
- 50  
51 1) CBC and biochemical profiles will be checked once a week during the treatment  
52  
53 period.
  - 54  
55 2) Physical examination and nutritional score assessment are performed once a  
56  
57 week.  
58  
59  
60

1  
2  
3 3) Pulmonary function and CT are performed after 23 fractions to assess tumor  
4 regression and surgery opportunities.  
5  
6

7  
8 2. Post-treatment  
9

10 The follow-up period is 1 year or until the participant's death. All participants  
11 are followed at 1 month after radiotherapy and every 3 months thereafter or as needed  
12 clinically. Routine follow-up should include clinical symptoms, CBC, tumor markers,  
13 contrast-enhanced CT, upper gastrointestinal contrast, pulmonary function.  
14 Gastroscopy is recommended to be reviewed for the first year. If there is a suspicion  
15 of recurrence, another gastroscopy can be performed. If necessary, PET-CT imaging  
16 and brain MR can be performed.  
17  
18  
19  
20  
21  
22  
23  
24  
25

26 ***Statistical analysis***  
27

28 According to the retrospective study in the authors' hospital and literature  
29 review,<sup>7 8 29-31</sup> it is assumed that the occurrence rate of RILI grade  $\geq 2$  in the control  
30 group will be 25% and that in the pirfenidone group will be 10%. This trial is  
31 designed as a randomized phase 2 study with a two-sided  $\alpha$  of 0.20 and a power of  
32 80%,<sup>32</sup> using PASS version 15.0.5 to calculate the sample size. In a phase 2 screening  
33 design, a higher  $\alpha$  level than the 0.05 level is used for the next phase 3 design. If the  
34 phase 2 trial is positive, such a positive result is not usually considered definitive  
35 without a subsequent phase 3 trial. In this study, 36 participants should be included in  
36 each group with  $\alpha$  of 0.2 and power of 80%. Considering a dropout rate of 20%, it is  
37 planned to enroll about 88 participants.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

51 All analyses will be performed using SAS Version 9.3 (SAS Institute, Cary, NC,  
52 USA). The t-test will be used for continuous data. The chi-square test and Fisher's  
53 exact probability method will be used for categorical data. The survival rate will be  
54 calculated using the Kaplan-Meier method, and comparisons between groups will be  
55  
56  
57  
58  
59  
60

1  
2  
3 performed using the log-rank test. The confidence interval of the survival distribution  
4  
5 will be calculated according to Greenwood's formula. A proportional hazard  
6  
7 regression model for risk will be estimated using hazard ratios.  $P < 0.05$  will be  
8  
9 considered statistically significant.  
10

### 11 ***Data collection and management***

12  
13 All clinical data will be collected by a research assistant and recorded in detail in  
14  
15 the predesigned electronic table. All written informed consent will be stored in a  
16  
17 separate closet, and only the main researchers can access the relevant research data.  
18  
19 All study procedures were developed to ensure data protection and confidentiality.  
20  
21  
22

### 23 ***Dissemination***

24  
25 The results will be disseminated in international peer-reviewed conferences and  
26  
27 journals.  
28  
29

### 30 ***Patient and public involvement***

31  
32 The patients and the public were not involved in the development of this protocol.  
33  
34  
35  
36

### 37 **Discussion**

38  
39 RILI is an important dose-limiting factor in thorax cancer radiotherapy. It is  
40  
41 commonly categorized into the acute injury stage, radiation pneumonitis (RP), and the  
42  
43 subsequent chronic injury stage, i.e., radiation pulmonary fibrosis (RPF). Immediately  
44  
45 after radiation exposure, damage to type I and II alveolar epithelial cells leads to  
46  
47 vascular permeability, cytokine release, and inflammatory cell infiltration, causing  
48  
49 acute pneumonitis. Then, injury repair in the late phase results in pulmonary fibrosis  
50  
51  
52  
53  
54  
55

56 The only FDA-approved cytoprotective agent is amifostine, but its limited  
57  
58 effectiveness and adverse reactions prevent its clinical application.<sup>14 15 34 35</sup>  
59  
60

1  
2  
3 Consequently, there is a great focus on agents that are clinically applicable, especially  
4  
5 for the prevention of RILI.  
6

7  
8 Pirfenidone is a small molecule biosynthetic drug with anti-inflammatory,  
9  
10 anti-fibrosis, and antioxidant effects.<sup>16-18 36</sup> The FDA approved it for the management  
11  
12 of IPF.<sup>23 24 37-39</sup> As RILI has similar pathological processes and clinical manifestations  
13  
14 as IPF, characterized by cell infiltration, interstitial edema, and interstitial fibrosis of  
15  
16 the alveolar wall,<sup>26</sup> pirfenidone is promising in the prevention and treatment of RILI.  
17  
18 Ji et al.<sup>40</sup> found that pirfenidone could significantly reduce inflammation and collagen  
19  
20 deposition through decreasing macrophages and hydroxyproline levels in alveolar  
21  
22 macrophages and lung tissues of irradiated rats by 62% and 24%, respectively.  
23  
24 Another in vitro experiment by Qin et al.<sup>27</sup> showed that pirfenidone prevented RILI  
25  
26 by suppressing the expression of TGF- $\beta$ 1 and phosphorylation of Smad3 in lung  
27  
28 tissues and significantly prolong the survival of rats after irradiation (>140 days vs. 73  
29  
30 days,  $P < 0.01$ ). Sun et al.<sup>41</sup> also confirmed the prevention from pelvic fibrosis caused  
31  
32 by radiotherapy for rectal cancer.  
33  
34  
35  
36

37  
38 As early as 2007, an open-label, prospective pilot study<sup>42</sup> was carried out to  
39  
40 ameliorate established radiation-induced fibrosis of the neck, back, or extremities that  
41  
42 caused at least a moderately severe loss of range of motion. The results reported an  
43  
44 improvement of the function of at least 25% and subjective improvement.  
45  
46

47  
48 Currently, a national multicenter study on the treatment of RILI with pirfenidone  
49  
50 led by Prof. Wang and Prof. Chen is ongoing (NCT03902509). Still, no clinical study  
51  
52 on the prevention of RILI with pirfenidone has been reported. According to its  
53  
54 mechanism, pirfenidone is supposed to be promising in preventing RILI. Since the  
55  
56 target volume, target location, and radiotherapy dose for esophageal cancer and lung  
57  
58 cancer are different, this preliminary study was designed to explore the efficacy of  
59  
60

1  
2  
3 pirfenidone in preventing RILI, focusing on patients with middle and upper ESCC.  
4

5 The present randomized, placebo-controlled, double-blind, single-center phase 2  
6 trial is designed to determine the efficacy and safety of pirfenidone in preventing RILI  
7 in participants with locally advanced ESCC undergoing CCRT. The results might  
8 provide new options for the prevention of RILI. Further research is needed to confirm  
9 the efficacy of pirfenidone for the prevention of RILI in a multicenter phase 3 trial  
10 with larger sample size.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20

### 21 **List of abbreviations**

22  
23  
24 AE: adverse event; AFP:  $\alpha$ -fetoprotein; ALT: alanine transaminase; ANC: absolute  
25 neutrophil count; AST: aspartate transaminase; CA: cancer antigen; CCr: creatinine  
26 clearance rate; CEA: carcinoembryonic antigen; CT: computed tomography; CTV:  
27 clinical target volume; Cyfra21-1: soluble fragment of cytokeratin 1; DFS:  
28 disease-free survival; Dmax: maximal dose; ECOG: Eastern Cooperative Oncology  
29 Group; FGF: fibroblast growth factor; GTV: gross tumor volume; IL: interleukin;  
30 IPF: idiopathic pulmonary fibrosis; MD: mean dose; NRS: nutritional risk scale; NSE:  
31 neuron-specific enolase; OS: overall survival; PDGF: platelet-derived growth factor;  
32 PET: positron emission tomography; PTV: planned target volume; RILI:  
33 radiation-induced lung injury; SCC: squamous cell carcinoma antigen; SCr: serum  
34 creatinine; TGF: tumor growth factor; TNF: tumor necrosis factor; ULN: upper limit  
35 of normal; WBC: white blood cells.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## **Acknowledgements**

We thank all the patients who will participate in this trial and all participating doctors and investigators who devote their time and passion to the implementation of this study. We thank Beijing Continent Pharmaceutical Co., Ltd. for providing both the pirfenidone and placebo capsules.

## **Authors' contributions**

XBH is the principal investigator responsible for study design, revised the article critically, and approved the final version to be published. Chen Cheng mainly participated in protocol design and writing. ZBW and YY is responsible for statistical and study design. Chen Chun and KMQ are responsible for surgery indication. XD, CRX, LSQ and ZHL made a substantial contribution to the design of the study. All authors read and approved the final manuscript.

## **Funding**

The study was granted by The Fourth Batch of Hospital Key Discipline Construction Program of Fujian Medical University Union Hospital (No. 2021FLK01KY).

## **Competing interest statement**

All authors declare that they have no competing interests.

## **Consent for publication**

Not applicable.

## **Ethics approval and consent to participate**

The study protocol was approved by the Ethics Committee of Fujian Union Hospital (No. 2021YF001-02). Signed informed consent from each participant is required. The trial has been registered in chictr.org.cn (ChiCTR2100043032).

## **Provenance and peer review**

Not commissioned; externally peer reviewed.

1  
2  
3 **Data availability statement**  
4

5 Not applicable – data collection is still ongoing.  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## References

1. Torre LA, Bray F, Siegel RL, *et al.* Global cancer statistics, 2012. *CA Cancer J Clin* 2015;65(2):87-108.
2. Herskovic A, Martz K, al-Sarraf M, *et al.* Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. *N Engl J Med* 1992;326(24):1593-8.
3. Cooper JS, Guo MD, Herskovic A, *et al.* Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. *JAMA* 1999;281(17):1623-7.
4. Minsky BD, Pajak TF, Ginsberg RJ, *et al.* INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. *J Clin Oncol* 2002;20(5):1167-74.
5. Li QQ, Liu MZ, Hu YH, *et al.* Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma. *Dis Esophagus* 2010;23(3):253-9.
6. Du F, Wang Q, Wang W, *et al.* Analysis of related factors of radiation pneumonitis after radiotherapy for thoracic segment esophageal cancer. *Zhong Hua Fang She Yi Xue Yu Fang Hu Za Zhi* 2020;40(11):832-39.
7. Cao Y, Shen W, Zhu S. Low Dose Volume of Lung in Predicting Acute Radiation Pneumonitis in Patients with Middle and Lower Thoracic Esophageal Cancer.

- 1  
2  
3  
4 *Zhong Liu Fang Zhi Yan Jiu* 2015;0(1):32–36.  
5  
6  
7 8. Zhen L, Zhao S, Xu C, *et al.* Clinical and dosimetric factors associated with acute  
8  
9 radiation-induced pneumonitis in esophageal carcinoma patients after intensity  
10  
11 modulated radiation therapy (IMRT). *Zhen Duan Xue Li Lun Yu Shi Jian*  
12  
13 2019;0(1):66–71.  
14  
15  
16  
17 9. Wu W, Tan Y, Xiao N, *et al.* Analysis of influencing factors of radiation-induced  
18  
19 lung injury in patients with esophageal cancer treated by IMRT. *Tian Jin Yi*  
20  
21 *Yao* 2019;0(2):159–62.  
22  
23  
24  
25 10. Fu WH, Wang LH, Zhou ZM, *et al.* Comparison of conformal and  
26  
27 intensity-modulated techniques for simultaneous integrated boost radiotherapy  
28  
29 of upper esophageal carcinoma. *World J Gastroenterol* 2004;10(8):1098-102.  
30  
31  
32  
33 11. Wang L, Liang S, Li C, *et al.* A Novel Nomogram and Risk Classification System  
34  
35 Predicting Radiation Pneumonitis in Patients With Esophageal Cancer  
36  
37 Receiving Radiation Therapy. *Int J Radiat Oncol Biol Phys*  
38  
39 2019;105(5):1074-85.  
40  
41  
42  
43 12. Chandra A, Guerrero TM, Liu HH, *et al.* Feasibility of using intensity-modulated  
44  
45 radiotherapy to improve lung sparing in treatment planning for distal  
46  
47 esophageal cancer. *Radiother Oncol* 2005;77(3):247-53.  
48  
49  
50  
51 13. Shen W, Xu J, Li S, *et al.* Prognostic analysis of intensity-modulated radiotherapy  
52  
53 for cervical and upper thoracic esophageal carcinoma. *Zhong Hua Fang She*  
54  
55 *Zhong Liu Xue Za Zhi* 2020;29(10):842–48.  
56  
57  
58  
59 14. Oditura M, De Vita F, Belli A, *et al.* Efficacy and safety profile of amifostine in  
60

- 1  
2  
3  
4 the preoperative combined therapy of esophageal cancer patients. *Oncol Rep*  
5  
6 2000;7(2):397-400.  
7  
8
- 9 15. Jatoi A, Martenson JA, Foster NR, *et al.* Paclitaxel, carboplatin, 5-fluorouracil,  
10  
11 and radiation for locally advanced esophageal cancer: phase II results of  
12  
13 preliminary pharmacologic and molecular efforts to mitigate toxicity and  
14  
15 predict outcomes: North Central Cancer Treatment Group (N0044). *Am J Clin*  
16  
17 *Oncol* 2007;30(5):507-13.  
18  
19
- 20 16. Oku H, Nakazato H, Horikawa T, *et al.* Pirfenidone suppresses tumor necrosis  
21  
22 factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock.  
23  
24 *Eur J Pharmacol* 2002;446(1-3):167-76.  
25  
26
- 27 17. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on procollagen gene  
28  
29 expression at the transcriptional level in bleomycin hamster model of lung  
30  
31 fibrosis. *J Pharmacol Exp Ther* 1999;289(1):211-8.  
32  
33
- 34 18. Misra HP, Rabideau C. Pirfenidone inhibits NADPH-dependent microsomal lipid  
35  
36 peroxidation and scavenges hydroxyl radicals. *Mol Cell Biochem*  
37  
38 2000;204(1-2):119-26.  
39  
40
- 41 19. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming  
42  
43 growth factor-beta gene expression at the transcriptional level in bleomycin  
44  
45 hamster model of lung fibrosis. *J Pharmacol Exp Ther* 1999;291(1):367-73.  
46  
47
- 48 20. Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits PDGF isoforms  
49  
50 in bleomycin hamster model of lung fibrosis at the translational level. *Am J*  
51  
52 *Physiol* 1999;276(2):L311-8.  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 21. Iyer SN, Wild JS, Schiedt MJ, *et al.* Dietary intake of pirfenidone ameliorates  
5  
6 bleomycin-induced lung fibrosis in hamsters. *J Lab Clin Med*  
7  
8  
9 1995;125(6):779-85.  
10  
11  
12 22. Kehrer JP, Margolin SB. Pirfenidone diminishes cyclophosphamide-induced lung  
13  
14 fibrosis in mice. *Toxicol Lett* 1997;90(2-3):125-32.  
15  
16  
17 23. Margaritopoulos GA, Trachalaki A, Wells AU, *et al.* Pirfenidone improves  
18  
19 survival in IPF: results from a real-life study. *BMC Pulm Med* 2018;18(1):177.  
20  
21  
22 24. Adams TN, Eiswirth C, Newton CA, *et al.* Pirfenidone for Idiopathic Pulmonary  
23  
24 Fibrosis. *Am J Respir Crit Care Med* 2016;194(3):374-6.  
25  
26  
27 25. Ying HJ, Fang M, Chen M. Progress in the mechanism of radiation-induced lung  
28  
29 injury. *Chin Med J (Engl)* 2020;134(2):161-63.  
30  
31  
32 26. Turkkan G, Willems Y, Hendriks LEL, *et al.* Idiopathic pulmonary fibrosis:  
33  
34 Current knowledge, future perspectives and its importance in radiation  
35  
36 oncology. *Radiother Oncol* 2021;155:269-77.  
37  
38  
39 27. Qin W, Liu B, Yi M, *et al.* Antifibrotic Agent Pirfenidone Protects against  
40  
41 Development of Radiation-Induced Pulmonary Fibrosis in a Murine Model.  
42  
43 *Radiat Res* 2018;190(4):396-403.  
44  
45  
46  
47 28. National Comprehensive Cancer Network. Esophageal and Esophagogastric  
48  
49 Junction Cancers (version 3.2021).  
50  
51  
52  
53 29. Asakura H, Hashimoto T, Zenda S, *et al.* Analysis of dose-volume histogram  
54  
55 parameters for radiation pneumonitis after definitive concurrent  
56  
57 chemoradiotherapy for esophageal cancer. *Radiother Oncol* 2010;95(2):240-4.  
58  
59  
60

- 1  
2  
3  
4 30. Ishida K, Ando N, Yamamoto S, *et al.* Phase II study of cisplatin and  
5  
6 5-fluorouracil with concurrent radiotherapy in advanced squamous cell  
7  
8 carcinoma of the esophagus: a Japan Esophageal Oncology Group  
9  
10 (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). *Jpn J Clin Oncol*  
11  
12 2004;34(10):615-9.  
13  
14  
15  
16  
17 31. chen C, Zeng B, Xue D. Preliminary report of pirfenidone for the prevention of  
18  
19 radiation pneumonitis in patients with esophageal cancer: analysis using  
20  
21 inverse probability of treatment weighting[J]. *Chin J Clin Oncol*  
22  
23 2021;48(15):772-76.  
24  
25  
26  
27 32. Rubinstein LV, Korn EL, Freidlin B, *et al.* Design issues of randomized phase II  
28  
29 trials and a proposal for phase II screening trials. *J Clin Oncol*  
30  
31 2005;23(28):7199-206.  
32  
33  
34  
35 33. Hanania AN, Mainwaring W, Ghebre YT, *et al.* Radiation-Induced Lung Injury:  
36  
37 Assessment and Management. *Chest* 2019;156(1):150-62.  
38  
39  
40 34. Jain V, Berman AT. Radiation Pneumonitis: Old Problem, New Tricks. *Cancers*  
41  
42 (*Basel*) 2018;10(7)  
43  
44  
45 35. Yahyapour R, Amini P, Rezapoor S, *et al.* Targeting of Inflammation for  
46  
47 Radiation Protection and Mitigation. *Curr Mol Pharmacol* 2018;11(3):203-10.  
48  
49  
50 36. Nakazato H, Oku H, Yamane S, *et al.* A novel anti-fibrotic agent pirfenidone  
51  
52 suppresses tumor necrosis factor-alpha at the translational level. *Eur J*  
53  
54 *Pharmacol* 2002;446(1-3):177-85.  
55  
56  
57  
58 37. Troy LK, Corte TJ. Therapy for idiopathic pulmonary fibrosis: lessons from  
59  
60

- 1  
2  
3  
4 pooled data analyses. *Eur Respir J* 2016;47(1):27-30.  
5  
6  
7 38. Noble PW, Albera C, Bradford WZ, *et al.* Pirfenidone for idiopathic pulmonary  
8  
9 fibrosis: analysis of pooled data from three multinational phase 3 trials. *Eur*  
10  
11 *Respir J* 2016;47(1):243-53.  
12  
13  
14 39. King TE, Jr., Bradford WZ, Castro-Bernardini S, *et al.* A phase 3 trial of  
15  
16 pirfenidone in patients with idiopathic pulmonary fibrosis. *N Engl J Med*  
17  
18 2014;370(22):2083-92.  
19  
20  
21  
22 40. Ji W, Jiang Y, Yang W, *et al.* Pirfenidone in prevention and treatment of radiation  
23  
24 pulmonary fibrosis. *Zhong Hua Fang She Zhong Liu Xue Za Zhi* 2010;6:560–  
25  
26 63.  
27  
28  
29  
30 41. Sun YW, Zhang YY, Ke XJ, *et al.* Pirfenidone prevents radiation-induced  
31  
32 intestinal fibrosis in rats by inhibiting fibroblast proliferation and  
33  
34 differentiation and suppressing the TGF-beta1/Smad/CTGF signaling  
35  
36 pathway. *Eur J Pharmacol* 2018;822:199-206.  
37  
38  
39  
40 42. Simone NL, Soule BP, Gerber L, *et al.* Oral pirfenidone in patients with chronic  
41  
42 fibrosis resulting from radiotherapy: a pilot study. *Radiat Oncol* 2007;2:19.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Figure legend**

**Figure 1.** Study flowchart.

For peer review only

**Table 1.** Full inclusion, exclusion and withdrawal criteria.

Inclusion criteria	Exclusion criteria	Withdrawal criteria
● Age between 18 and 75 years old.	● History of chest radiotherapy.	● Treatment delay for more than 2
● ECOG performance status of 0-1.	● Concomitant tumor in other organs	weeks or interruption due to extended
● Pathological confirmation of ESCC.	or prior malignancies within 5 years.	toxicity.
● Imaging staging suggests T <sub>3-4</sub> N+M0 thoracic esophageal cancer according to AJCC 8 staging (primary lesions are mainly in the chest cavity).	● History of interstitial lung disease or non-infectious pneumonia.	● Disease progression is judged by researchers during treatment.
● No restriction on the number of regional nodal stations or bulk of disease.	● Severe cardiovascular disease, cerebrovascular complications, epilepsy, active peptic ulcers, infections, psychological disorders, or other serious underlying diseases	
● Patients who cannot tolerate surgery or the tumor cannot be removed surgically.	that may limit their understanding	
● No perforation or deep niche in the esophageal cancer lesion.	and tolerance of comprehensive	
● No prior chemotherapy, immunotherapy, or surgery	treatments.	

- 
- 1  
2  
3  
4  
5 before radiotherapy.
- 6 ● Able to eat liquid food.
  - 7 ● Adequate bone marrow, liver, kidney, blood
  - 8 coagulation function, and lung functions.
  - 9 ● Life expectancy of >6 months.
  - 10 ● Voluntary participation in the study, with good
  - 11 expected compliance.
- 12 ● Patients with a previous history of
  - 13 ataxia due to telangiectasia or other
  - 14 radiosensitivity reaction.
  - 15 ● Patients with scleroderma or active
  - 16 connective tissue disease.
- 

17  
18  
19  
20  
21 ECOG, Eastern Cooperative Oncology Group; ESCC, esophageal squamous cell carcinoma; AJCC, American Joint Committee on Cancer; CT,  
22  
23 computed tomography.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46




Figure 1. Study flowchart.

170x194mm (300 x 300 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Page No
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
	2b	All items from the World Health Organization Trial Registration Data Set	3
Protocol version	3	Date and version identifier	/
Funding	4	Sources and types of financial, material, and other support	13
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1,2,13
	5b	Name and contact information for the trial sponsor	/
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	13,14
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	13,14
<b>Introduction</b>			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	3-4
	6b	Explanation for choice of comparators	4
Objectives	7	Specific objectives or hypotheses	5

Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	5
<b>Methods: Participants, interventions, and outcomes</b>			
Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	5
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	5, Table 1
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	6-8
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	8
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	8
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	8
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	9
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	5-9, Figure 1
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	10
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	/
<b>Methods: Assignment of interventions (for controlled trials)</b>			
Allocation:			

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	8
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	8
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	/
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	8
	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	/
<b>Methods: Data collection, management, and analysis</b>			
Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	5-6,9
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	9
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	10
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	10
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	/
	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	10

<b>Methods: Monitoring</b>			
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	10
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	/
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	9
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	/
<b>Ethics and dissemination</b>			
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	13
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	/
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	5,13
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	/
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	10
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	13
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	10
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	/



1 2 3 4 5 6	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	10
7 8 9		31b	Authorship eligibility guidelines and any intended use of professional writers	/
10 11 12 13		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	10
14 15	<b>Appendices</b>			
16 17 18	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	/
19 20 21 22 23	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	/

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.

# BMJ Open

## Pirfenidone for the prevention of radiation-induced lung injury in patients with locally advanced esophageal squamous cell carcinoma: A randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-060619.R1
Article Type:	Protocol
Date Submitted by the Author:	13-Jun-2022
Complete List of Authors:	<p>Chen, Cheng; Fujian Medical University Union Hospital, Department of Radiation Oncology, Clinical Research Center for Radiology and Radiotherapy of Fujian Province (Digestive, Hematological, and Breast Malignancies); Fujian Medical University, College of Medical Technology and Engineering, Union Clinical Medical College, Fujian Key Laboratory of Intelligent Imaging and Precision Radiotherapy for Tumors  Zeng, Bangwei; Fujian Medical University Union Hospital, Nosocomial Infection Control Branch  Xue, Dan; Fujian Medical University Union Hospital, Pulmonary Department  Cao, Rongxiang; Fujian Medical University Union Hospital, Pulmonary Department  Liao, Siqin; Fujian Medical University Union Hospital, Department of PET/CT Center  Yang, Yong; Fujian Medical University Union Hospital, Department of Radiation Oncology, Clinical Research Center for Radiology and Radiotherapy of Fujian Province (Digestive, Hematological, and Breast Malignancies); Fujian Medical University, College of Medical Technology and Engineering, Union Clinical Medical College, Fujian Key Laboratory of Intelligent Imaging and Precision Radiotherapy for Tumors  Li, Zhihua; No.1 Hospital of Longhai, Department of Oncology Department  Kang, Mingqiang; Fujian Medical University Union Hospital, Department of Thoracic Surgery  Chen, Chun; Fujian Medical University Union Hospital, Department of Thoracic Surgery  Xu, Benhua; Fujian Medical University Union Hospital, Department of Radiation Oncology, Clinical Research Center for Radiology and Radiotherapy of Fujian Province (Digestive, Hematological, and Breast Malignancies); Fujian Medical University, College of Medical Technology and Engineering, Union Clinical Medical College, Fujian Key Laboratory of Intelligent Imaging and Precision Radiotherapy for Tumors</p>
<b>Primary Subject Heading</b>:	Oncology
Secondary Subject Heading:	Pharmacology and therapeutics, Respiratory medicine
Keywords:	Adult oncology < ONCOLOGY, Radiation oncology < RADIOLOGY &

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

	IMAGING, Adult radiotherapy < RADIOTHERAPY, Radiation oncology < RADIOTHERAPY

SCHOLARONE™  
Manuscripts

1  
2  
3 **Pirfenidone for the prevention of radiation-induced lung injury in patients with**  
4 **locally advanced esophageal squamous cell carcinoma: A randomized controlled**  
5 **trial**  
6  
7  
8  
9

10  
11  
12  
13  
14 Cheng Chen<sup>1, 4, 5, 6, 10</sup>, Bangwei Zeng<sup>2</sup>, Dan Xue<sup>3</sup>, Rongxiang Cao<sup>3</sup>, Siqin Liao<sup>7</sup>, Yong  
15 Yang<sup>1, 4, 5, 6, 10</sup>, Zhihua Li<sup>9</sup>, Mingqiang Kang<sup>8</sup>, Chun Chen<sup>8</sup>, Benhua Xu<sup>1, 4, 5, 6, 10\*</sup>  
16  
17  
18  
19  
20  
21

22 <sup>1</sup>Department of Radiation Oncology, Fujian Medical University Union Hospital,  
23 Fuzhou 350000, China  
24  
25

26  
27 <sup>2</sup>Nosocomial Infection Control Branch, Fujian Medical University Union Hospital,  
28 Fuzhou 350000, China  
29  
30

31  
32 <sup>3</sup>Pulmonary Department, Fujian Medical University Union Hospital, Fuzhou 350000,  
33 China  
34  
35

36  
37 <sup>4</sup>College of Medical Technology and Engineering, Fujian Medical University, Fuzhou  
38 350000, China  
39  
40

41  
42 <sup>5</sup>Union Clinical Medical College, Fujian Medical University, Fuzhou 350000, China  
43  
44

45  
46 <sup>6</sup> Fujian Key Laboratory of Intelligent Imaging and Precision Radiotherapy for Tumors,  
47 Fujian Medical University  
48  
49

50  
51 <sup>7</sup>Department of PET/CT Center, Fujian Medical University Union Hospital, Fuzhou  
52 350000, China  
53  
54

1  
2  
3<sup>8</sup>Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou  
4  
5  
6 350000, China  
7

8  
9<sup>9</sup>Department of Oncology Department, No.1 Hospital of Longhai, Zhangzhou 363199,  
10  
11 China  
12

13  
14<sup>10</sup>Clinical Research Center for Radiology and Radiotherapy of Fujian Province  
15  
16 (Digestive, Hematological, and Breast Malignancies)  
17  
18

19  
20  
21  
22 **\*Corresponding author:**  
23

24  
25 Benhua Xu  
26

27  
28 Department of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou  
29  
30 350000, China  
31

32  
33 College of Medical Technology and Engineering, Fujian Medical University, Fuzhou  
34  
35 350000, China  
36

37  
38 Union Clinical Medical College, Fujian Medical University, Fuzhou 350000, China  
39

40  
41 Fujian Key Laboratory of Intelligent Imaging and Precision Radiotherapy for Tumors,  
42  
43 Fujian Medical University  
44

45  
46 Clinical Research Center for Radiology and Radiotherapy of Fujian Province  
47  
48 (Digestive, Hematological, and Breast Malignancies)  
49

50  
51  
52 Tel: +86-13365910602  
53

54  
55 E-mail: benhuaxu@163.com  
56  
57  
58  
59  
60

## Abstract

**Introduction:** Radiation-induced lung injury (RILI) is among the most clinically-challenging toxicities and dose-limiting factors during and/or after thoracic radiation therapy for esophageal squamous cell carcinoma (ESCC). With limited effective protective drugs against RILI, the main strategy to reduce the injury is strict adherence to dose-volume restrictions of normal lungs. RILI can manifest as acute radiation pneumonitis of cellular injury, cytokine release, and cytokine recruitment to inflammatory infiltrate, and subsequent chronic radiation pulmonary fibrosis. Pirfenidone inhibits inflammatory cytokines, scavenges free radicals, and reduces hydroxyproline and collagen formation. Hence, pirfenidone might be a promising drug for RILI prevention. This study aimed to evaluate the efficacy and safety of pirfenidone in preventing RILI in patients with locally advanced ESCC receiving chemoradiotherapy.

**Methods and analysis:** This study is designed as a randomized, placebo-controlled, double-blinded, single-center phase 2 trial and will explore whether the addition of pirfenidone during concurrent chemoradiation therapy (CCRT) will prevent RILI in patients with locally advanced ESCC unsuitable for surgery. Eligible participants will be randomized at 1:1 to pirfenidone or placebo group. The primary endpoint is the incidence of grade  $\geq 2$  RILI. The secondary endpoints include the incidence of any grade other than grade  $> 2$  RILI, the time to the occurrence of RILI, the changes in pulmonary function after CCRT, the completion rate of CCRT, disease-free survival (DFS), and overall survival (OS). The follow-up period will be 1 year. If the results meet the primary endpoint of this trial, a phase 3 multicenter trial with a larger sample size will be required to substantiate the evidence of benefits of pirfenidone for preventing RILI.

### **Ethics and dissemination**

This study was approved by the Ethics Committee of Fujian Union Hospital (No. 2021YF001-02). The findings of the trial will be disseminated through peer-reviewed journals, and national and international conference presentations.

**Trial registration:** ChiCTR2100043032

### **Strengths and limitations of this study**

- This is the first randomized controlled trial to explore the efficacy and safety of pirfenidone in preventing RILI.
- It is a double-blinded trial that neither patients nor physicians will know the treatment allocation.
- It is a phase 2 trial performed at a single center.
- The dosage of radiation was inconsistent, with patients with unresectable patients receiving 50 Gy to 60 Gy, and with patients in the process of downstaging receiving 40 Gy due to further option to surgical resection.

**Key words:** Pirfenidone; radiation-induced lung injury; prevention; esophageal squamous cell carcinoma; concurrent chemoradiation therapy; randomized controlled trial.

## Introduction

Esophageal cancer ranks the eighth most common cancer worldwide. Among the 477,900 new patients reported globally per year, nearly a half number of the cases occur in China, and 90% of them are ESCC.<sup>1</sup> The definitive standard of care for unresectable locally advanced ESCC remains concurrent chemoradiation therapy, with a 3-year OS rate of 30%-37%.<sup>2-5</sup> Because the lungs often lay in the path of the treatment radiation beams, RILI is inevitable. It is one of the most common side effects and potentially dose-limiting toxicities of radiotherapy for esophageal cancer, with an incidence of about 10.7%-35.14%.<sup>6-11</sup> Furthermore, RILI during radiation can delay or even interrupt radiotherapy, resulting in poor local control of the disease, increased financial burden, and even death.

Although advanced radiotherapy technologies such as intensity-modulated radiation therapy (IMRT) are superior to traditional 2D and 3D conformal radiation therapies regarding dosimetry and organ protection,<sup>10 12</sup> many patients still develop varying degrees of RILI.<sup>13</sup> In clinical practice, there is no specific treatment for RILI except oxygen inhalation, glucocorticoid administration, and application of antibiotics when necessary. Therefore, preventing RILI is of greater clinical significance than treating it. Although amifostine was approved by the US Food & Drug Administration (FDA) for radiotherapy protection, it did not efficiently protect against RILI during the course of treatments for esophageal cancer.<sup>14 15</sup> Moreover, its clinical application is limited owing to the high price and high rates of its side effects. Therefore, there are a few effective protective strategies against RILI during radiation therapy for patients with ESCC.

Pirfenidone is an active small-molecular oral drug that can inhibit the



1  
2  
3 overexpression of transforming growth factor (TGF)- $\beta$ 1 and meanwhile reduce the  
4 secretion of platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF),  
5 thereby inhibiting the biological activity of fibroblasts.<sup>16-18</sup> Pharmacodynamic  
6 experiments showed that pirfenidone had satisfying effects against lung inflammation  
7 and fibrosis.<sup>19-22</sup> The FDA approved pirfenidone in 2014 for the treatment of idiopathic  
8 pulmonary fibrosis (IPF),<sup>23 24</sup> which shares some common pathological manifestations  
9 with RILI.<sup>25 26</sup> A previous study in mice showed that pirfenidone could attenuate RILI.<sup>27</sup>  
10 A phase 2 trial is under recruitment stage and aims to confirm the efficacy of  
11 pirfenidone for the treatment of RILI (ClinicalTrials.gov NCT03902509).  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

25 There are no published clinical data to assess the prophylactic preventive role of  
26 pirfenidone against RILI. Therefore, this randomized, placebo-controlled, double-  
27 blinded, single-center, phase 2 trial is designed to examine whether pirfenidone can  
28 reduce the occurrence of RILI in patients with locally advanced ESCC receiving CCRT.  
29  
30  
31  
32  
33  
34  
35  
36  
37

## 38 **Methods**

### 39 *Study design and participants*

40  
41  
42  
43 This study is a randomized, placebo-controlled, double-blinded, single-center,  
44 phase 2 clinical trial to examine the preventative role of pirfenidone for RILI in patients  
45 with unresectable locally advanced ESCC at diagnosis undergoing CCRT. The  
46 participants will be randomized at 1:1 to the pirfenidone or control groups. Figure 1  
47 depicts the overview of the study procedure.  
48  
49  
50  
51  
52  
53  
54

55 The full inclusion, exclusion, and withdrawal criteria are listed in Table 1.  
56  
57

58 All eligible patients should provide a written informed consent and be willing to  
59  
60

1  
2  
3 participate in and complete the study and follow-up.  
4  
5

### 6 ***Pre-treatment assessment and screening*** 7

8  
9 Each patient must complete the following examinations and undergo counseling  
10 within 1 or 2 weeks before the onset of the trial:  
11  
12

- 13 1) Detailed medical history review.
- 14 2) Physical examination (height, weight, vital signs, and Eastern Cooperative  
15 Oncology Group (ECOG) performance status).  
16
- 17 3) Blood tests, including complete blood counts (CBC), biochemical profiles,  
18 coagulation function, hepatitis B virus (HBV) screening and HBV DNA (for HBsAg-  
19 positive patients), esophageal cancer-related tumor markers such as carcinoembryonic  
20 antigen (CEA), cancer antigen (CA) 199, CA125, CA153, neuron-specific enolase  
21 (NSE), squamous cell carcinoma antigen (SCC), soluble fragment of cytokeratin 19  
22 (Cyfra21-1), and  $\alpha$ -fetoprotein (AFP).  
23
- 24 4) Cardiopulmonary function evaluation, including electrocardiogram, ultrasonic  
25 cardiogram, and pulmonary function assessment.  
26
- 27 5) Upper gastrointestinal endoscopy and biopsy.  
28
- 29 6) Imaging, including chest/abdominal computed tomography (CT) with intravenous  
30 contrast and upper gastrointestinal swallowed meglumine diatrizoate contrast, pelvic  
31 CT with contrast as clinically indicated, and [18F] fluorodeoxyglucose positron  
32 emission tomography/computed tomography ([18F] FDG-PET/CT) evaluation if the  
33 patient agreed to undergo, leading to more accurate staging.  
34
- 35 7) Nutritional assessment and counseling.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 8) Smoking cessation advice.  
4  
5

### 6 ***Radiotherapy*** 7

8  
9  
10 The target contour principle is as follows. Gross tumor volume (GTV) include the  
11 primary tumor (GTVp) and enlarged regional lymph nodes (GTVn), and are determined  
12 by the CT simulation scan and other diagnostic imagings. Elective node irradiation  
13 (ENI) will be used for clinical target volume (CTV) delineation. CTV of GTVp is  
14 defined as the primary tumor volume plus a 3cm margin expansion in superior and  
15 inferior along the length of the esophagus and a 0.5-1cm radial expansion including the  
16 para-esophageal lymph nodes. CTV of GTVn will cover all lymph nodes involved and  
17 high-risk lymphatic drainage regions such as the supraclavicular for the super-thoracic  
18 and middle-thoracic sections.<sup>28</sup> Planning target volume (PTV) for GTV and CTV will  
19 be created by expanding with a uniform margin of 0.5 cm separately. The recommended  
20 dose to PTV-CTV and PTV-GTV are 50.4 Gy/1.8 Gy/28 fractions and 60 Gy/1.8 Gy/33  
21 fractions, respectively. If the target area is large and OAR can't be achieved, only PTV-  
22 GTV irradiation or PTV-CTV irradiation can be performed as decided by the treating  
23 radiotherapist. The administering dose will cover at least 95% of the PTV. Normal  
24 tissue tolerance dose-limits are listed in Table 2. All patients will be positioned supine  
25 on the treatment couch and fixed by a custom-fitted thermoplastic sheet and the setup  
26 imaging will be acquired every day before treatment to correct the treatment position  
27 by OBI image system. IMRT is recommended when the treatment plans were designed.  
28 Because the dose calculation for areas with artifacts generates heterogeneity, leading to  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 high dose deviation. To ensure the quality of radiotherapy delivered, the Acuros XB  
5  
6 (version 15.5) dose algorithm which was reported to be as accurate as or close to the  
7  
8 Monte Carlo simulation (MC) method will be employed in this present study. The  
9  
10 treatment plan for all patients will be verified using phantom named Delta4, and the  
11  
12 gamma passing rate at the criteria of 3%/3 mm will be ensured greater than 98%.  
13  
14  
15

16  
17 Resectability will be re-assessed by a multidisciplinary team at irradiation with  
18  
19 41.4 Gy. If surgical resection is possible, radiation therapy will be terminated, and the  
20  
21 surgery will be performed after 4-8 weeks after termination of radiation.  
22  
23

### 24 ***Chemotherapy***

25  
26  
27 The participants will receive docetaxel at 60 mg/m<sup>2</sup> intravenously on day 1 and  
28  
29 cisplatin at 30 mg/m<sup>2</sup> intravenously on days 1 and 2 (DP regimen) for two cycles.  
30  
31 Polyethylene glycol recombinant human granulocyte colony-stimulating factor (PEG-  
32  
33 rhG-CSF) is recommended for prevention of neutropenia during CCRT. Dose  
34  
35 modification will be based on the preceding cycle CBC and biochemical markers. The  
36  
37 chemotherapy will be continued if 1) absolute neutrophil count (ANC) is  $\geq 1.5 \times 10^9/L$ ,  
38  
39 2) platelet count is  $\geq 100 \times 10^9/L$ , 3) alanine transaminase (ALT), aspartate transaminase  
40  
41 (AST), and total bilirubin are of Common Terminology Criteria for Adverse Events  
42  
43 (CTCAE) grade  $< 2$ , and 4) non-hematological toxicity (except for hair loss) returns  
44  
45 to grade 1 or baseline level. The doses of both drugs will be decreased by 20% if any  
46  
47 grade 3 or higher toxicities are observed. If grade 3 or 4 radiation pneumonitis occurs,  
48  
49 radiotherapy and concurrent chemotherapy will be terminated.  
50  
51  
52  
53  
54  
55

### 56 ***Randomization and intervention***

1  
2  
3 The participants will be randomized at 1:1 to the pirfenidone or control groups  
4 using a random number table and stratified based on the tolerability or inability to  
5 surgery. Participants and doctors will be masked to treatment allocation. Identical  
6 pirfenidone and placebo capsules are provided by Beijing Continent Pharmaceutical  
7 Co., Ltd. The appearance, smell, taste, and properties of the placebo are the same as the  
8 study drug. Each capsule contains 100 mg of drug or placebo. In the first week, the  
9 dosage will be 200 mg/time, 3 times/day. In the second week, the dosage will be  
10 increased to 300 mg/time, 3 times/day. In weeks 3-12, the dosage will be increased to  
11 400 mg/time, 3 times/day. The pirfenidone treatment will start on the day when  
12 radiotherapy will be initiated and lasted for 12 weeks. The capsules will be taken during  
13 or after meals as gastrointestinal reactions are the most common adverse effects of  
14 pirfenidone. Photosensitivity is another common adverse event. External use of  
15 sunscreen and avoiding the sun during medication can effectively reduce the incidence  
16 and severity of photosensitivity reactions. If the adverse events still occur or cannot be  
17 tolerated even after the dose is reduced, the drug will be temporarily discontinued for  
18 1-2 weeks until the participant tolerates the symptoms. Once the adverse events are  
19 alleviated or can be tolerated, the participant will retake pirfenidone. The physician can  
20 decide whether to stop the drug intake according to the situation. The pirfenidone  
21 treatment will be permanently discontinued if severe adverse events occur, including  
22 liver dysfunction, jaundice, severe hypersensitivity, and photosensitivity.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

### 50 ***Concomitant medication***

51  
52  
53 Drugs that may prevent or treat fibrosis are forbidden, such as amifostine and  
54 thalidomide. The participants should avoid the concurrent use of drugs that increase the  
55 adverse reactions of pirfenidone, including ciprofloxacin, amiodarone, and  
56  
57  
58  
59  
60

propafenone. The participants should also avoid the concurrently receipt of medications that can reduce the efficacy of pirfenidone, such as omeprazole and rifampin.

### ***Endpoints***

The primary endpoint is the incidence of grade 2 or higher RILI in participants of the full analysis set (FAS) and per-protocol set (PPS). RILI will be evaluated according to CTCAE version 5.0.<sup>29</sup> within 1 year. The secondary endpoints include the incidence of RILI of any grade, the time to the occurrence of RILI, and changes in pulmonary function after radiotherapy, the completion rate of CCRT, disease-free survival (DFS), and overall survival (OS).

RLIL is a diagnosis established by clinical suspicion or radiological findings after excluding other lung pathologies such as pre-existing pathologies and pulmonary infection. It often appears with no specific symptom, vital signs, laboratory profiling or imaging tests. Familiar history of radiation and recognition of RILI are of utmost importance in the context of regular follow-up. Diagnosis and grading will be confirmed by review by multidisciplinary senior physicians, including a radiation oncologist, a pulmonologist, and a radiologist. History, physical, chest CT, and previous radiotherapy will be evaluated at every follow-up during personal visits when available. RILI will be scored based on the CTCAE version 5.0 classifying symptoms and image findings will be used to classify into five grades<sup>29</sup> As far as the symptom, dyspnea and dry cough are the most common manifestation-in acute lung injury.<sup>30</sup> Occasional fever is usually mild, but high fever is sometimes reflective of co-infectious pneumonitis. The chronic RF is a slowly progressing respiratory disease that can

1  
2  
3  
4 manifest as respiratory insufficiency. In terms of physical symptoms, the physical  
5  
6 examination findings may be normal or include pleural rub, moist rales, and signs of  
7  
8 consolidation. Chest imaging, particular lung CT at baseline and follow-up are critical  
9  
10 in the diagnosis and grading. In acute phase, which usually appears 4-8 weeks after  
11  
12 radiotherapy, CT images may display exudative changes such as multiple small patchy  
13  
14 or flock-shaped ground glass density shadows in the irradiation field, with fuzzy edge  
15  
16 and unclear boundary with surrounding lung tissue. In phase of consolidation, which  
17  
18 usually occurs 2-3 months after radiotherapy, CT images may display patchy high-  
19  
20 density consolidation in the irradiation field, not distributed according to the lung lobe  
21  
22 and lung segment, accompanied by partial air bronchial signs. In the stage of fibrosis,  
23  
24 which usually occurs six months after radiotherapy, CT images may show density  
25  
26 enhancement shadows of grid, cord, and patchy shape in the irradiation field with clear  
27  
28 boundaries, accompanied by thickened pleura, lung volume reduction, lung hilum  
29  
30 reduction, ipsilateral vascular texture thinning, and compensatory increase in  
31  
32 contralateral lung volume.<sup>31-35</sup>  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 Considering the anti-inflammatory and anti-fibrotic properties of pirfenidone, the  
45  
46 grade will be scored at the maximal level in the case who experiences with RP and RF.  
47  
48 When one case shows grade 3 RP and grade 2 RF, it will be recorded as grade 3 for the  
49  
50 primary endpoint.  
51  
52  
53  
54  
55

### 56 ***Follow-up***

57  
58  
59  
60

- 1
- 2
- 3 1. During the period of intervention
- 4
- 5
- 6 1) CBC and biochemical profiles will be verified once a week.
- 7
- 8
- 9 2) Physical examination and nutritional score assessment will be performed once a
- 10
- 11 week.
- 12
- 13
- 14 3) Pulmonary function and chest/abdominal CT will be performed after 23 fractions
- 15
- 16 to assess tumor regression and surgery opportunities.
- 17
- 18
- 19
- 20 2. Post-treatment
- 21

22 The follow-up period is 1 year or until the participant's death. All participants will  
23 be followed at 1 month after radiotherapy and every 3 months thereafter or as needed  
24 clinically. Routine follow-up will include assessment of clinical symptoms, CBC and  
25 tumor markers, performing contrast-enhanced CT and upper gastrointestinal contrast,  
26 and pulmonary function evaluation. Repeated gastroscopy is recommended for the first  
27 year. If recurrence has is suspected, physical examination, radiography, and  
28 pathological examination will be performed.

### 39 ***Statistical analysis***

40  
41  
42 Based on the retrospective study in the authors' hospital and literature reviews,<sup>7 8</sup>  
43  
44 <sup>36-38</sup> it is assumed that the occurrence rate of RILI of grade  $\geq 2$  in the control group will  
45 be 25% and that in the pirfenidone group will be 10%. This trial is designed as a  
46 randomized phase 2 study with a two-sided  $\alpha$  of 0.20 and a power of 80%,<sup>39</sup> using PASS  
47 software version 15.0.5 to calculate the sample size. From a phase 2 screening design,  
48 a higher  $\alpha$  level than the 0.05 level will be used for the next phase 3 design. If the phase  
49 2 trial is positive, such a positive result is not usually considered definitive without a  
50 subsequent phase 3 trial. In this study, 36 participants will be included in each group



1  
2  
3 with  $\alpha$ -level of 0.2 and power of 80%. Considering a dropout rate of 20%, it is planned  
4  
5 to enroll about 88 participants.  
6  
7

8 All analyses will be performed using SAS version 9.3 (SAS Institute, Cary, NC,  
9 USA). The t-test will be used for analyzing continuous data. The chi-square test and  
10 Fisher's exact probability method will be used for analyzing categorical data. The  
11 survival rate will be calculated using the Kaplan-Meier method, and comparisons  
12 between groups will be performed using the log-rank test. The confidence interval of  
13 the survival distribution will be calculated according to Greenwood's formula. A  
14 proportional hazard regression model for risk will be estimated using hazard ratios.  
15  $P < 0.05$  will be considered statistically significant.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

### 26 27 ***Data collection and management*** 28

29 All clinical data will be collected by a research assistant and recorded in detail in  
30 the predesigned electronic table. All written informed consent will be stored in a  
31 separate closet, and only the researchers can access the relevant research data. All study  
32 procedures were developed to ensure data protection and confidentiality.  
33  
34  
35  
36  
37  
38  
39

### 40 ***Dissemination*** 41

42 The results will be disseminated in international peer-reviewed conferences and  
43 journals.  
44  
45  
46  
47

### 48 ***Patient and public involvement*** 49

50 Patients and the public are not involved in the design or conduct of the study or the  
51 outcome measures.  
52  
53  
54  
55

### 56 **Discussion** 57 58 59 60

1  
2  
3  
4 For many years, radiotherapy (RT) has been employed for the treatment of  
5  
6 esophageal cancer as curative or palliative. However, RILI is a common and severe side  
7  
8 effect of radiation, which can delay or interrupt antitumor therapy, resulting in poor  
9  
10 local control of the disease, impaired quality of life, and even death. Therefore,  
11  
12 prophylactic drugs to minimize the toxicity and maximize efficacy of RT are required.  
13  
14  
15 Until now the only FDA-approved cytoprotective agent is amifostine, but its limited  
16  
17 effectiveness and significant side-effect prevent its clinical application.<sup>14, 15, 34, 35</sup>  
18  
19  
20 Consequently, pharmaceutical agents that are clinically applicable, especially for the  
21  
22 prevention of RILI are being focused<sup>40-42</sup>Pirfenidone is a small molecular biosynthetic  
23  
24 drug with anti-inflammatory, anti-fibrotic, and antioxidant properties,<sup>16-18 43</sup> which was  
25  
26 approved by the FDA for the management of IPF.<sup>23 24 44-46</sup> As RILI has similar  
27  
28 pathogenesis and clinical manifestations as IPF, characterized by cell infiltration,  
29  
30 interstitial edema, and interstitial fibrosis of the alveolar wall,<sup>26</sup> pirfenidone may hold  
31  
32 promise for prevention and treatment of RILI, which has been tested in preclinical and  
33  
34 pilot studies.<sup>47, 27, 48, 49</sup> Currently, a multicenter phase II study on the treatment of RILI  
35  
36 with pirfenidone is being carried out (NCT03902509), but no clinical study on the  
37  
38 prevention has been reported. This is the first phase II study designed to explore the  
39  
40 efficacy of pirfenidone in preventing RILI.  
41  
42  
43  
44  
45  
46  
47  
48  
49

50  
51 Most published data on RILI was derived from lung cancer. However, differences  
52  
53 in anatomy, pathogenesis, and treatment between lung and esophageal tumors limit the  
54  
55 extrapolation of radiation pneumonitis (RP) prediction model of pulmonary tumors to  
56  
57 esophageal tumors. This preliminary study was designed to focus on patients with  
58  
59  
60

1  
2  
3  
4 thoracic ESCC. Additionally, from the current NCCN guidelines and expert  
5  
6 recommendations, tolerance dose-limits for lung vary from V20 of  $\leq 20\%$  for  
7  
8 esophageal and esophagogastric junction cancers, and V20 of  $\leq 35\%$ - $40\%$  for non-small  
9  
10 cell lung cancer. Obviously, esophageal cancer has more stringent restrictions on V20,  
11  
12 which can be achieved by esophageal adenocarcinoma (EA) treatment plan, since it  
13  
14 mainly presents in the lower thoracic area in European and American countries. But  
15  
16 esophageal squamous cell carcinoma (ESCC),<sup>50 51</sup> highly prevalent in China and Asia,  
17  
18 are often located in the upper or middle esophagus. Therefore, comparing to EA in  
19  
20 which the RT area is close to the abdomen and the lung is relatively well protected,  
21  
22 patients of thoracic ESCC is at risk of lung exposure and may require particular  
23  
24 attention.<sup>52</sup> Consequently, the tolerance dose-limit of lung is recommended as V20 $\leq 28$ -  
25  
26 30%, V5 $\leq 60\%$ , and MLD 15 Gy<sup>53</sup> in the present study.  
27  
28  
29  
30  
31  
32  
33  
34

35 The estimated incidence of RILI varies widely across esophageal cancer studies  
36  
37 from 3.33% to 35% of grade 2 lung injury, and 0% to 21% of grade 3 lung injury. It is  
38  
39 likely due to variations of target delineation, radiation dose, radiotherapy techniques,<sup>10-</sup>  
40  
41 <sup>12 36 54-58</sup> and classification systems. Since consensus of the optimal radiation strategy  
42  
43 for nodal irradiation is lacking and accuracy of imaging diagnosis is insufficient<sup>59</sup> FDG-  
44  
45 PET/CT at diagnosis is strongly recommended. Further, the elective nodal irradiation  
46  
47 (ENI) is adopted depending on the location of the primary tumor.-Although the dose of  
48  
49 50 Gy is the standard for CCRT in most Western countries, 60 Gy dose using modern  
50  
51 radiation technologies is more preferred by clinicians in Asian countries based on the  
52  
53 belief that 50 Gy may not be enough for ESCC.<sup>53 60 61</sup> Consequently, 60 Gy dose to  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 PTV-GTV and 50.4 Gy dose PTV-CTV will be administered in the present study.  
5  
6  
7 However, only PTV-GTV or PTV-CTV irradiation is permitted when normal tissue  
8  
9 constraints cannot be met by therapy, which is decided by the physician. Additionally,  
10  
11 due to the anatomical features of esophagus, including the lack of serosa and the  
12  
13 presence of numerous organs surrounding the esophagus, most patients in this trial have  
14  
15 cT4N+M0 thoracic esophageal cancer. Till now, the standard treatment for the  
16  
17 cT4N+M0 thoracic esophageal cancer has not been established, and therefore,  
18  
19 definitive chemoradiotherapy (CRT) or chemoradiotherapy plus conversional surgery  
20  
21 for down-staging patients are both accepted treatment.<sup>61</sup> The major difference between  
22  
23 neoadjuvant and definitive CRT is the radiation dose (41.4 Gy VS. 50-60 Gy) which is  
24  
25 the most crucial factor that influences the development of RILI. For this reason,  
26  
27 stratified random cluster sampling is applied for balancing two groups.  
28  
29  
30  
31  
32  
33

34  
35 Considering the anti-inflammatory and anti-fibrotic properties<sup>16-18,43</sup>, the incidence  
36  
37 of grade 2 or higher RILI is the primary endpoint to test the prevention of symptomatic  
38  
39 RP and RF. As known, the diagnosis of RILI is challenging due to differential or  
40  
41 concomitant diagnoses such as infections and exacerbation of pre-existing pulmonary  
42  
43 conditions. Particularly, in some cases that pneumonia patches in the radiation beam  
44  
45 pathway as well as RP complicated with infectious pneumonia could not be identified.<sup>58</sup>  
46  
47  
48 In addition, RP grading is limited by subjectivity especially in diagnosing grade 2 and  
49  
50 grade 3. Therefore, the classification will be confirmed by a board-certified radiation  
51  
52 oncologist referring to a joint expert consultation. The multidisciplinary team consists  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 of a senior radiation oncologist, a pulmonologist, and a radiologist with experience in  
5  
6 RILI.  
7

8  
9 In summary, the present study design was endeavored to control for most of the  
10  
11 important risk factors for RILI as describe above. The results might provide new  
12  
13 options for the prevention of RILI. However, owing to the limited sample size, further  
14  
15 research is required to substantiate the efficacy of pirfenidone for the prevention of  
16  
17 RILI using a multicenter phase 3 trial with larger sample size.  
18  
19

### 20 21 22 23 24 **List of abbreviations**

25  
26  
27 AE: adverse event; AFP:  $\alpha$ -fetoprotein; ALT: alanine transaminase; ANC: absolute  
28  
29 neutrophil count; AST: aspartate transaminase; CA: cancer antigen; CBC: complete  
30  
31 blood counts; CCr: creatinine clearance rate; CEA: carcinoembryonic antigen; CT:  
32  
33 computed tomography; CTCAE : Common Terminology Criteria for Adverse Events;  
34  
35 CTV: clinical target volume; Cyfra21-1: soluble fragment of cytokeratin 1; DFS:  
36  
37 disease-free survival; Dmax: maximal dose; ECOG: Eastern Cooperative Oncology  
38  
39 Group; ESCC: esophageal squamous cell carcinoma; FDG-PET/CT : [18F]  
40  
41 fluorodeoxyglucose positron emission tomography/computed; FGF: fibroblast growth  
42  
43 factor; FDA: Food & Drug Administration; GTV: gross tumor volume; HBV: hepatitis  
44  
45 B virus; IL: interleukin; IMRT: intensity-modulated radiation therapy; IPF: idiopathic  
46  
47 pulmonary fibrosis; MLD: mean lung dose;  
48  
49

50  
51  
52 NRS: nutritional risk scale; NSE: neuron-specific enolase; OAR: organs at risk; OS:  
53  
54 overall survival; PDGF: platelet-derived growth factor; PEG-rhG-CSF: Polyethylene  
55  
56  
57  
58  
59  
60

1  
2  
3 glycol recombinant human granulocyte colony-stimulating factor; PTV: planned target  
4  
5 volume; RILI: radiation-induced lung injury; RP: radiation pneumonitis; SCC:  
6  
7 squamous cell carcinoma antigen; SCr: serum creatinine; TGF: tumor growth factor;  
8  
9  
10 TNF: tumor necrosis factor; ULN: upper limit of normal; WBC: white blood cells.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Acknowledgements

We thank all the patients who will participate in this trial and all participating doctors and investigators who devoted their time and passion to the implementation of this study. We are grateful to Xiaobo Li and Jianping Zhang for their contribution to the revision of the manuscript. We thank Beijing Continent Pharmaceutical Co., Ltd. for providing both the pirfenidone and placebo capsules.

## Authors' contributions

XBH is the principal investigator responsible for study design, revised the article critically, and approved the final version to be published. Chen Cheng mainly participated in protocol design and writing. ZBW and YY are responsible for statistical and study design. Chen Chun and KMQ are responsible for surgery recommendation. XD, CRX, LSQ and ZHL made a substantial contribution to the design of the study. All authors read and approved the final manuscript.

## Funding

The pirfenidone and placebo are provided by Beijing Continent Pharmaceuticals Co., Ltd (no grant number). The study was granted by the Fourth Batch of Hospital Key Discipline Construction Program of Fujian Medical University Union Hospital (No. 2021FLK01KY). They had no roles in study design, in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.

## Competing interest statement

All authors declare that they have no competing interests.

1  
2  
3 **Consent for publication**  
4  
5

6 Not applicable.  
7  
8

9 **Ethics approval and consent to participate**  
10

11  
12 The study protocol was approved by the Ethics Committee of Fujian Union Hospital  
13  
14 (No. 2021YF001-02). Signed informed consent from each participant is required. The  
15  
16 trial was registered in chictr.org.cn (ChiCTR2100043032).  
17  
18

19 **Provenance and peer review**  
20

21  
22 Not commissioned; externally peer reviewed.  
23  
24

25 **Data availability statement**  
26

27  
28 Not applicable – data collection is still ongoing.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## References

1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. *CA Cancer J Clin* 2015;65(2):87-108. doi: 10.3322/caac.21262 [published Online First: 2015/02/06]
2. Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. *N Engl J Med* 1992;326(24):1593-8. doi: 10.1056/NEJM199206113262403 [published Online First: 1992/06/11]
3. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. *JAMA* 1999;281(17):1623-7. doi: 10.1001/jama.281.17.1623 [published Online First: 1999/05/11]
4. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. *J Clin Oncol* 2002;20(5):1167-74. doi: 10.1200/JCO.2002.20.5.1167 [published Online First: 2002/03/01]
5. Li QQ, Liu MZ, Hu YH, et al. Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma. *Dis Esophagus*

- 2010;23(3):253-9. doi: 10.1111/j.1442-2050.2009.01003.x [published Online First: 2009/09/08]
6. Du F, Wang Q, Wang W, et al. Analysis of related factors of radiation pneumonitis after radiotherapy for thoracic segment esophageal cancer. *Zhong Hua Fang She Yi Xue Yu Fang Hu Za Zhi* 2020;40(11):832–39.
7. Cao Y, Shen W, Zhu S. Low Dose Volume of Lung in Predicting Acute Radiation Pneumonitis in Patients with Middle and Lower Thoracic Esophageal Cancer. *Zhong Liu Fang Zhi Yan Jiu* 2015;0(1):32–36.
8. Zhen L, Zhao S, Xu C, et al. Clinical and dosimetric factors associated with acute radiation-induced pneumonitis in esophageal carcinoma patients after intensity modulated radiation therapy (IMRT). *Zhen Duan Xue Li Lun Yu Shi Jian* 2019;0(1):66–71.
9. Wu W, Tan Y, Xiao N, et al. Analysis of influencing factors of radiation-induced lung injury in patients with esophageal cancer treated by IMRT. *Tian Jin Yi Yao* 2019;0(2):159–62.
10. Fu WH, Wang LH, Zhou ZM, et al. Comparison of conformal and intensity-modulated techniques for simultaneous integrated boost radiotherapy of upper esophageal carcinoma. *World J Gastroenterol* 2004;10(8):1098-102. doi: 10.3748/wjg.v10.i8.1098 [published Online First: 2004/04/08]
11. Wang L, Liang S, Li C, et al. A Novel Nomogram and Risk Classification System

- 1  
2  
3  
4 Predicting Radiation Pneumonitis in Patients With Esophageal Cancer  
5  
6 Receiving Radiation Therapy. *Int J Radiat Oncol Biol Phys* 2019;105(5):1074-  
7  
8 85. doi: 10.1016/j.ijrobp.2019.08.024 [published Online First: 2019/08/29]  
9  
10  
11  
12 12. Chandra A, Guerrero TM, Liu HH, et al. Feasibility of using intensity-modulated  
13  
14 radiotherapy to improve lung sparing in treatment planning for distal esophageal  
15  
16 cancer. *Radiother Oncol* 2005;77(3):247-53. doi:  
17  
18 10.1016/j.radonc.2005.10.017 [published Online First: 2005/11/22]  
19  
20  
21  
22  
23 13. Shen W, Xu J, Li S, et al. Prognostic analysis of intensity-modulated radiotherapy  
24  
25 for cervical and upper thoracic esophageal carcinoma. *Zhong Hua Fang She*  
26  
27 *Zhong Liu Xue Za Zhi* 2020;29(10):842–48.  
28  
29  
30  
31  
32 14. Orditura M, De Vita F, Belli A, et al. Efficacy and safety profile of amifostine in  
33  
34 the preoperative combined therapy of esophageal cancer patients. *Oncol Rep*  
35  
36 2000;7(2):397-400. doi: 10.3892/or.7.2.397 [published Online First:  
37  
38 2000/02/15]  
39  
40  
41  
42  
43 15. Jatoi A, Martenson JA, Foster NR, et al. Paclitaxel, carboplatin, 5-fluorouracil, and  
44  
45 radiation for locally advanced esophageal cancer: phase II results of preliminary  
46  
47 pharmacologic and molecular efforts to mitigate toxicity and predict outcomes:  
48  
49 North Central Cancer Treatment Group (N0044). *Am J Clin Oncol*  
50  
51 2007;30(5):507-13. doi: 10.1097/COC.0b013e31805c139a [published Online  
52  
53 First: 2007/10/09]  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 16. Oku H, Nakazato H, Horikawa T, et al. Pirfenidone suppresses tumor necrosis  
5  
6 factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock.  
7  
8  
9 *Eur J Pharmacol* 2002;446(1-3):167-76. doi: 10.1016/s0014-2999(02)01757-0  
10  
11 [published Online First: 2002/07/06]  
12  
13  
14  
15 17. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on procollagen gene  
16  
17 expression at the transcriptional level in bleomycin hamster model of lung  
18  
19 fibrosis. *J Pharmacol Exp Ther* 1999;289(1):211-8. [published Online First:  
20  
21 1999/03/23]  
22  
23  
24  
25  
26 18. Misra HP, Rabideau C. Pirfenidone inhibits NADPH-dependent microsomal lipid  
27  
28 peroxidation and scavenges hydroxyl radicals. *Mol Cell Biochem* 2000;204(1-  
29  
30 2):119-26. doi: 10.1023/a:1007023532508 [published Online First: 2000/03/16]  
31  
32  
33  
34  
35 19. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming  
36  
37 growth factor-beta gene expression at the transcriptional level in bleomycin  
38  
39 hamster model of lung fibrosis. *J Pharmacol Exp Ther* 1999;291(1):367-73.  
40  
41 [published Online First: 1999/09/22]  
42  
43  
44  
45  
46 20. Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits PDGF isoforms  
47  
48 in bleomycin hamster model of lung fibrosis at the translational level. *Am J*  
49  
50 *Physiol* 1999;276(2):L311-8. doi: 10.1152/ajplung.1999.276.2.L311 [published  
51  
52 Online First: 1999/02/10]  
53  
54  
55  
56  
57 21. Iyer SN, Wild JS, Schiedt MJ, et al. Dietary intake of pirfenidone ameliorates  
58  
59  
60

- 1  
2  
3  
4 bleomycin-induced lung fibrosis in hamsters. *J Lab Clin Med* 1995;125(6):779-  
5  
6  
7 85. [published Online First: 1995/06/01]  
8  
9  
10 22. Kehrer JP, Margolin SB. Pirfenidone diminishes cyclophosphamide-induced lung  
11  
12 fibrosis in mice. *Toxicol Lett* 1997;90(2-3):125-32. doi: 10.1016/s0378-  
13  
14 4274(96)03845-3 [published Online First: 1997/02/07]  
15  
16  
17  
18 23. Margaritopoulos GA, Trachalaki A, Wells AU, et al. Pirfenidone improves survival  
19  
20 in IPF: results from a real-life study. *BMC Pulm Med* 2018;18(1):177. doi:  
21  
22 10.1186/s12890-018-0736-z [published Online First: 2018/11/25]  
23  
24  
25  
26 24. Adams TN, Eiswirth C, Newton CA, et al. Pirfenidone for Idiopathic Pulmonary  
27  
28 Fibrosis. *Am J Respir Crit Care Med* 2016;194(3):374-6. doi:  
29  
30 10.1164/rccm.201602-0258RR [published Online First: 2016/06/01]  
31  
32  
33  
34 25. Ying HJ, Fang M, Chen M. Progress in the mechanism of radiation-induced lung  
35  
36 injury. *Chin Med J (Engl)* 2020;134(2):161-63. doi:  
37  
38 10.1097/CM9.0000000000001032 [published Online First: 2020/09/06]  
39  
40  
41  
42  
43 26. Turkkan G, Willems Y, Hendriks LEL, et al. Idiopathic pulmonary fibrosis: Current  
44  
45 knowledge, future perspectives and its importance in radiation oncology.  
46  
47 *Radiother Oncol* 2021;155:269-77. doi: 10.1016/j.radonc.2020.11.020  
48  
49 [published Online First: 2020/11/28]  
50  
51  
52  
53  
54 27. Qin W, Liu B, Yi M, et al. Antifibrotic Agent Pirfenidone Protects against  
55  
56 Development of Radiation-Induced Pulmonary Fibrosis in a Murine Model.  
57  
58  
59  
60

- 1  
2  
3  
4 *Radiat Res* 2018;190(4):396-403. doi: 10.1667/RR15017.1 [published Online  
5  
6 First: 2018/07/18]  
7  
8  
9
- 10 28. National Comprehensive Cancer Network. Esophageal and Esophagogastric  
11  
12 Junction Cancers (version 3.2021).  
13  
14
- 15 29. USDOHAH S. Common Terminology Criteria for Adverse Events (CTCAE) 2017.  
16  
17 Available from:  
18  
19 [27](https://ctepcancer.gov/protocolDevelopment/electronic_applications/docs/CTC<br/>20<br/>21 <i>AE_v5_Quick_Reference_85x11.pdf</i>.<br/>22<br/>23<br/>24</a><br/>25</p><p>26 30. Rodrigues G, Lock M, D'Souza D, et al. Prediction of radiation pneumonitis by dose<br/>27<br/>28 - volume histogram parameters in lung cancer--a systematic review.<br/>29<br/>30 <i>Radiotherapy and oncology : journal of the European Society for Therapeutic<br/>31<br/>32 Radiology and Oncology</i> 2004;71(2):127-38. doi:<br/>33<br/>34 10.1016/j.radonc.2004.02.015 [published Online First: 2004/04/28]<br/>35<br/>36<br/>37<br/>38<br/>39</p><p>40 31. Larici AR, del Ciello A, Maggi F, et al. Lung abnormalities at multimodality<br/>41<br/>42 imaging after radiation therapy for non-small cell lung cancer. <i>Radiographics :</i><br/>43<br/>44 <i>a review publication of the Radiological Society of North America, Inc</i><br/>45<br/>46 2011;31(3):771-89. doi: 10.1148/rg.313105096 [published Online First:<br/>47<br/>48 2011/05/17]<br/>49<br/>50<br/>51<br/>52</p><p>53 32. Choi YW, Munden RF, Erasmus JJ, et al. Effects of radiation therapy on the lung:<br/>54<br/>55 radiologic appearances and differential diagnosis. <i>Radiographics : a review</i><br/>56<br/>57<br/>58<br/>59<br/>60</p></div><div data-bbox=)

- 1  
2  
3  
4 *publication of the Radiological Society of North America, Inc* 2004;24(4):985-  
5  
6 97; discussion 98. doi: 10.1148/rg.244035160 [published Online First:  
7  
8 2004/07/17]  
9  
10  
11  
12 33. Yamashita H, Takahashi W, Haga A, et al. Radiation pneumonitis after stereotactic  
13  
14 radiation therapy for lung cancer. *World journal of radiology* 2014;6(9):708-15.  
15  
16 doi: 10.4329/wjr.v6.i9.708 [published Online First: 2014/10/03]  
17  
18  
19  
20  
21 34. Linda A, Trovo M, Bradley JD. Radiation injury of the lung after stereotactic body  
22  
23 radiation therapy (SBRT) for lung cancer: a timeline and pattern of CT changes.  
24  
25 *European journal of radiology* 2011;79(1):147-54. doi:  
26  
27 10.1016/j.ejrad.2009.10.029 [published Online First: 2009/12/04]  
28  
29  
30  
31  
32 35. Ghaye B, Wanet M, El Hajjam M. Imaging after radiation therapy of thoracic  
33  
34 tumors. *Diagnostic and interventional imaging* 2016;97(10):1037-52. doi:  
35  
36 10.1016/j.diii.2016.06.019 [published Online First: 2016/08/29]  
37  
38  
39  
40  
41 36. Asakura H, Hashimoto T, Zenda S, et al. Analysis of dose-volume histogram  
42  
43 parameters for radiation pneumonitis after definitive concurrent  
44  
45 chemoradiotherapy for esophageal cancer. *Radiother Oncol* 2010;95(2):240-4.  
46  
47 doi: 10.1016/j.radonc.2010.02.006 [published Online First: 2010/03/13]  
48  
49  
50  
51  
52 37. Ishida K, Ando N, Yamamoto S, et al. Phase II study of cisplatin and 5-fluorouracil  
53  
54 with concurrent radiotherapy in advanced squamous cell carcinoma of the  
55  
56 esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical  
57  
58  
59  
60

- 1  
2  
3  
4 Oncology Group trial (JCOG9516). *Jpn J Clin Oncol* 2004;34(10):615-9. doi:  
5  
6 10.1093/jjco/hyh107 [published Online First: 2004/12/14]  
7  
8  
9  
10 38. chen C, Zeng B, Xue D. Preliminary report of pirfenidone for the prevention of  
11  
12 radiation pneumonitis in patients with esophageal cancer: analysis using inverse  
13  
14 probability of treatment weighting[J]. *Chin J Clin Oncol* 2021;48(15):772-76.  
15  
16  
17  
18 39. Rubinstein LV, Korn EL, Freidlin B, et al. Design issues of randomized phase II  
19  
20 trials and a proposal for phase II screening trials. *J Clin Oncol*  
21  
22 2005;23(28):7199-206. doi: 10.1200/JCO.2005.01.149 [published Online First:  
23  
24 2005/09/30]  
25  
26  
27  
28  
29 40. Ozturk B, Egehan I, Atavci S, et al. Pentoxifylline in prevention of radiation-  
30  
31 induced lung toxicity in patients with breast and lung cancer: a double-blind  
32  
33 randomized trial. *International journal of radiation oncology, biology, physics*  
34  
35 2004;58(1):213-9. doi: 10.1016/s0360-3016(03)01444-5 [published Online  
36  
37 First: 2003/12/31]  
38  
39  
40  
41  
42  
43 41. Ghosh SN, Zhang R, Fish BL, et al. Renin-Angiotensin system suppression  
44  
45 mitigates experimental radiation pneumonitis. *International journal of*  
46  
47 *radiation oncology, biology, physics* 2009;75(5):1528-36. doi:  
48  
49 10.1016/j.ijrobp.2009.07.1743 [published Online First: 2009/11/26]  
50  
51  
52  
53  
54 42. Kharofa J, Cohen EP, Tomic R, et al. Decreased risk of radiation pneumonitis with  
55  
56 incidental concurrent use of angiotensin-converting enzyme inhibitors and  
57  
58  
59  
60



- 1  
2  
3  
4 thoracic radiation therapy. *International journal of radiation oncology, biology,*  
5  
6  
7 *physics* 2012;84(1):238-43. doi: 10.1016/j.ijrobp.2011.11.013 [published  
8  
9 Online First: 2012/02/04]  
10  
11  
12 43. Nakazato H, Oku H, Yamane S, et al. A novel anti-fibrotic agent pirfenidone  
13  
14 suppresses tumor necrosis factor-alpha at the translational level. *Eur J*  
15  
16 *Pharmacol* 2002;446(1-3):177-85. doi: 10.1016/s0014-2999(02)01758-2  
17  
18 [published Online First: 2002/07/06]  
19  
20  
21  
22  
23 44. Troy LK, Corte TJ. Therapy for idiopathic pulmonary fibrosis: lessons from pooled  
24  
25 data analyses. *Eur Respir J* 2016;47(1):27-30. doi: 10.1183/13993003.01669-  
26  
27 2015 [published Online First: 2016/01/02]  
28  
29  
30  
31  
32 45. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone for idiopathic pulmonary  
33  
34 fibrosis: analysis of pooled data from three multinational phase 3 trials. *Eur*  
35  
36 *Respir J* 2016;47(1):243-53. doi: 10.1183/13993003.00026-2015 [published  
37  
38 Online First: 2015/12/10]  
39  
40  
41  
42  
43 46. King TE, Jr., Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone  
44  
45 in patients with idiopathic pulmonary fibrosis. *N Engl J Med*  
46  
47 2014;370(22):2083-92. doi: 10.1056/NEJMoa1402582 [published Online First:  
48  
49 2014/05/20]  
50  
51  
52  
53  
54 47. Ji W, Jiang Y, Yang W, et al. Pirfenidone in prevention and treatment of radiation  
55  
56 pulmonary fibrosis. *Zhong Hua Fang She Zhong Liu Xue Za Zhi* 2010;6:560-  
57  
58  
59  
60

- 1  
2  
3  
4 63.  
5  
6  
7  
8 48. Sun YW, Zhang YY, Ke XJ, et al. Pirfenidone prevents radiation-induced intestinal  
9  
10 fibrosis in rats by inhibiting fibroblast proliferation and differentiation and  
11  
12 suppressing the TGF-beta1/Smad/CTGF signaling pathway. *Eur J Pharmacol*  
13  
14 2018;822:199-206. doi: 10.1016/j.ejphar.2018.01.027 [published Online First:  
15  
16 2018/01/29]  
17  
18  
19  
20  
21 49. Simone NL, Soule BP, Gerber L, et al. Oral pirfenidone in patients with chronic  
22  
23 fibrosis resulting from radiotherapy: a pilot study. *Radiat Oncol* 2007;2:19. doi:  
24  
25 10.1186/1748-717X-2-19 [published Online First: 2007/06/02]  
26  
27  
28  
29 50. Rustgi AK, El-Serag HB. Esophageal carcinoma. *The New England journal of*  
30  
31 *medicine* 2014;371(26):2499-509. doi: 10.1056/NEJMra1314530 [published  
32  
33 Online First: 2014/12/30]  
34  
35  
36  
37  
38 51. Arnold M, Ferlay J, van Berge Henegouwen MI, et al. Global burden of oesophageal  
39  
40 and gastric cancer by histology and subsite in 2018. *Gut* 2020;69(9):1564-71.  
41  
42 doi: 10.1136/gutjnl-2020-321600 [published Online First: 2020/07/02]  
43  
44  
45  
46 52. Stiles BM, Altorki NK. The NeoRes trial: questioning the benefit of radiation  
47  
48 therapy as part of neoadjuvant therapy for esophageal adenocarcinoma. *Journal*  
49  
50 *of thoracic disease* 2017;9(10):3465-68. doi: 10.21037/jtd.2017.08.146  
51  
52 [published Online First: 2017/12/23]  
53  
54  
55  
56  
57 53. National Health Commission Of The People's Republic Of C. Chinese guidelines  
58  
59  
60

- 1  
2  
3  
4 for diagnosis and treatment of esophageal carcinoma 2018 (English version).  
5  
6 *Chinese journal of cancer research = Chung-kuo yen cheng yen chiu*  
7  
8  
9 2019;31(2):223-58. doi: 10.21147/j.issn.1000-9604.2019.02.01 [published  
10  
11  
12 Online First: 2019/06/04]  
13  
14  
15 54. Ishikura S, Nihei K, Ohtsu A, et al. Long-term toxicity after definitive  
16  
17 chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus.  
18  
19 *Journal of clinical oncology : official journal of the American Society of*  
20  
21 *Clinical Oncology* 2003;21(14):2697-702. doi: 10.1200/jco.2003.03.055  
22  
23 [published Online First: 2003/07/16]  
24  
25  
26  
27  
28 55. Suntharalingam M, Winter K, Ilson D, et al. Effect of the Addition of Cetuximab to  
29  
30 Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal  
31  
32 Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial.  
33  
34 *JAMA oncology* 2017;3(11):1520-28. doi: 10.1001/jamaoncol.2017.1598  
35  
36  
37 [published Online First: 2017/07/09]  
38  
39  
40  
41  
42 56. Shi Z, Foley KG, Pablo de Mey J, et al. External Validation of Radiation-Induced  
43  
44 Dyspnea Models on Esophageal Cancer Radiotherapy Patients. *Frontiers in*  
45  
46 *oncology* 2019;9:1411. doi: 10.3389/fonc.2019.01411 [published Online First:  
47  
48 2020/01/11]  
49  
50  
51  
52  
53 57. Tonison JJ, Fischer SG, Viehrig M, et al. Radiation Pneumonitis after Intensity-  
54  
55 Modulated Radiotherapy for Esophageal Cancer: Institutional Data and a  
56  
57 Systematic Review. *Scientific reports* 2019;9(1):2255. doi: 10.1038/s41598-  
58  
59  
60

018-38414-5 [published Online First: 2019/02/21]

58. Hsieh HY, Yeh HL, Hsu CP, et al. Feasibility of intensity-modulated radiotherapy for esophageal cancer in definite chemoradiotherapy. *Journal of the Chinese Medical Association* : *JCMA* 2016;79(7):375-81. doi: 10.1016/j.jcma.2016.01.013 [published Online First: 2016/04/09]
59. Akiyama H, Tsurumaru M, Udagawa H, et al. Radical lymph node dissection for cancer of the thoracic esophagus. *Annals of surgery* 1994;220(3):364-72; discussion 72-3. doi: 10.1097/00000658-199409000-00012 [published Online First: 1994/09/01]
60. Zhang W, Luo Y, Wang X, et al. Dose-escalated radiotherapy improved survival for esophageal cancer patients with a clinical complete response after standard-dose radiotherapy with concurrent chemotherapy. *Cancer management and research* 2018;10:2675-82. doi: 10.2147/cmar.S160909 [published Online First: 2018/08/28]
61. Kuwano H, Nishimura Y, Oyama T, et al. Guidelines for Diagnosis and Treatment of Carcinoma of the Esophagus April 2012 edited by the Japan Esophageal Society. *Esophagus* : *official journal of the Japan Esophageal Society* 2015;12(1):1-30. doi: 10.1007/s10388-014-0465-1 [published Online First: 2015/01/27]

1  
2  
3 **Figure legend**  
4  
5

6 **Figure 1.** Flowchar of the study proceduarest.  
7  
8  
9

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

**Table 1.** Inclusion, exclusion and withdrawal criteria.

Inclusion criteria	Exclusion criteria	Withdrawal criteria
<ul style="list-style-type: none"> <li>● Age between 18 and 75 years old.</li> <li>● ECOG performance status of 0-1.</li> <li>● Pathological confirmation of ESCC.</li> <li>● Imaging staging suggests T<sub>3,4</sub>N+M0 thoracic esophageal cancer according to AJCC 8 staging (primary lesions are mainly in the chest cavity).</li> <li>● No restriction on the number of regional nodal stations or bulk of disease.</li> <li>● Patients who cannot tolerate surgery or the tumor cannot be removed surgically.</li> </ul>	<ul style="list-style-type: none"> <li>● History of chest radiotherapy.</li> <li>● Concomitant tumor in other organs or prior malignancies within 5 years.</li> <li>● History of interstitial lung disease or non-infectious pneumonia including COPD.</li> <li>● Severe cardiovascular disease, cerebrovascular complications, epilepsy, active peptic ulcers, infections, psychological disorders, or other serious underlying diseases</li> </ul>	<ul style="list-style-type: none"> <li>● Treatment delay for more than 2 weeks or interruption due to extended toxicity.</li> <li>● Disease progression is judged by researchers during treatment.</li> </ul>

- 
- No perforation or deep niche in the esophageal cancer lesion.
  - No prior chemotherapy, immunotherapy, or surgery before radiotherapy.
  - Able to eat liquid food.
  - Adequate bone marrow, liver, kidney, blood coagulation function, and lung functions.
  - Life expectancy of >6 months.
  - Voluntary participation in the study, with good compliance.
- that may limit their understanding and tolerance of comprehensive treatments.
  - Patients with a previous history of ataxia due to telangiectasia or other radiosensitivity reaction.
  - Patients with scleroderma or active connective tissue disease.

---

ECOG, Eastern Cooperative Oncology Group; ESCC, esophageal squamous cell carcinoma; AJCC, American Joint Committee on Cancer; CT, computed tomography.

**Table 2.** Dose limits for organs at risk (OAR)

OAR	Normal Tissue Dose-Volume Constraints
Lung	V20 $\leq$ 28%-30%, V5 $\leq$ 60%; MLD <15 Gy
Heart	V40 <30%, V40 $\leq$ 30%; Mean $\leq$ 30 Gy
Spinal cord	Max $\leq$ 45 Gy
Stomach	V40 <40%, Max $\leq$ 55-60 Gy
Liver	V30 <40%; Mean $\leq$ 25 Gy

V<sub>xx</sub>=% of the whole OAR receiving  $\geq$ xx Gy. Mld=mean lung dose



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1. Study flowchart.

170x194mm (300 x 300 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Page No
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
	2b	All items from the World Health Organization Trial Registration Data Set	3
Protocol version	3	Date and version identifier	/
Funding	4	Sources and types of financial, material, and other support	13
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1,2,13
	5b	Name and contact information for the trial sponsor	/
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	13,14
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	13,14
<b>Introduction</b>			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	3-4
	6b	Explanation for choice of comparators	4
Objectives	7	Specific objectives or hypotheses	5

Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	5
<b>Methods: Participants, interventions, and outcomes</b>			
Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	5
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	5, Table 1
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	6-8
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	8
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	8
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	8
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	9
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	5-9, Figure 1
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	10
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	/
<b>Methods: Assignment of interventions (for controlled trials)</b>			
Allocation:			

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	8
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	8
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	/
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	8
	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	/
<b>Methods: Data collection, management, and analysis</b>			
Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	5-6,9
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	9
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	10
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	10
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	/
	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	10

<b>Methods: Monitoring</b>			
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	10
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	/
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	9
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	/
<b>Ethics and dissemination</b>			
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	13
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	/
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	5,13
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	/
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	10
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	13
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	10
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	/

Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	10
	31b	Authorship eligibility guidelines and any intended use of professional writers	/
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	10
<b>Appendices</b>			
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	/
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	/

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.

# BMJ Open

## Pirfenidone for the prevention of radiation-induced lung injury in patients with locally advanced esophageal squamous cell carcinoma: A protocol for a randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-060619.R2
Article Type:	Protocol
Date Submitted by the Author:	28-Sep-2022
Complete List of Authors:	<p>Chen, Cheng; Fujian Medical University Union Hospital, Department of Radiation Oncology, Clinical Research Center for Radiology and Radiotherapy of Fujian Province (Digestive, Hematological, and Breast Malignancies); Fujian Medical University, College of Medical Technology and Engineering, Union Clinical Medical College, Fujian Key Laboratory of Intelligent Imaging and Precision Radiotherapy for Tumors</p> <p>Zeng, Bangwei; Fujian Medical University Union Hospital, Nosocomial Infection Control Branch</p> <p>Xue, Dan; Fujian Medical University Union Hospital, Pulmonary Department</p> <p>Cao, Rongxiang; Fujian Medical University Union Hospital, Pulmonary Department</p> <p>Liao, Siqin; Fujian Medical University Union Hospital, Department of PET/CT Center</p> <p>Yang, Yong; Fujian Medical University Union Hospital, Department of Radiation Oncology, Clinical Research Center for Radiology and Radiotherapy of Fujian Province (Digestive, Hematological, and Breast Malignancies); Fujian Medical University, College of Medical Technology and Engineering, Union Clinical Medical College, Fujian Key Laboratory of Intelligent Imaging and Precision Radiotherapy for Tumors</p> <p>Li, Zhihua; No.1 Hospital of Longhai, Department of Oncology Department</p> <p>Kang, Mingqiang; Fujian Medical University Union Hospital, Department of Thoracic Surgery</p> <p>Chen, Chun; Fujian Medical University Union Hospital, Department of Thoracic Surgery</p> <p>Xu, Benhua; Fujian Medical University Union Hospital, Department of Radiation Oncology, Clinical Research Center for Radiology and Radiotherapy of Fujian Province (Digestive, Hematological, and Breast Malignancies); Fujian Medical University, College of Medical Technology and Engineering, Union Clinical Medical College, Fujian Key Laboratory of Intelligent Imaging and Precision Radiotherapy for Tumors</p>
<b>Primary Subject Heading</b>:	Oncology
Secondary Subject Heading:	Pharmacology and therapeutics, Respiratory medicine

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Keywords:	Adult oncology < ONCOLOGY, Radiation oncology < RADIOLOGY & IMAGING, Adult radiotherapy < RADIOTHERAPY, Radiation oncology < RADIOTHERAPY

SCHOLARONE™  
Manuscripts



1  
2  
3 **Pirfenidone for the prevention of radiation-induced lung injury in patients with**  
4 **locally advanced esophageal squamous cell carcinoma: A protocol for a**  
5 **randomized controlled trial**  
6  
7  
8  
9

10 Cheng Chen<sup>1, 4, 5, 6, 10</sup>, Bangwei Zeng<sup>2</sup>, Dan Xue<sup>3</sup>, Rongxiang Cao<sup>3</sup>, Siqin Liao<sup>7</sup>, Yong  
11 Yang<sup>1, 4, 5, 6, 10</sup>, Zhihua Li<sup>9</sup>, Mingqiang Kang<sup>8</sup>, Chun Chen<sup>8</sup>, Benhua Xu<sup>1, 4, 5, 6, 10\*</sup>  
12  
13  
14  
15  
16  
17  
18

19 <sup>1</sup>Department of Radiation Oncology, Fujian Medical University Union Hospital,  
20 Fuzhou 350000, China  
21  
22

23  
24 <sup>2</sup>Nosocomial Infection Control Branch, Fujian Medical University Union Hospital,  
25 Fuzhou 350000, China  
26  
27

28  
29 <sup>3</sup>Pulmonary Department, Fujian Medical University Union Hospital, Fuzhou 350000,  
30 China  
31  
32

33  
34 <sup>4</sup>College of Medical Technology and Engineering, Fujian Medical University, Fuzhou  
35 350000, China  
36  
37

38  
39 <sup>5</sup>Union Clinical Medical College, Fujian Medical University, Fuzhou 350000, China  
40  
41

42  
43 <sup>6</sup> Fujian Key Laboratory of Intelligent Imaging and Precision Radiotherapy for Tumors,  
44 Fujian Medical University  
45  
46

47  
48 <sup>7</sup>Department of PET/CT Center, Fujian Medical University Union Hospital, Fuzhou  
49 350000, China  
50  
51

52  
53 <sup>8</sup>Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou  
54 350000, China  
55  
56

1  
2  
3<sup>9</sup>Department of Oncology Department, No.1 Hospital of Longhai, Zhangzhou 363199,  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

China

<sup>10</sup>Clinical Research Center for Radiology and Radiotherapy of Fujian Province  
(Digestive, Hematological, and Breast Malignancies)

**\*Corresponding author:**

Benhua Xu

Department of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou  
350000, China

College of Medical Technology and Engineering, Fujian Medical University, Fuzhou  
350000, China

Union Clinical Medical College, Fujian Medical University, Fuzhou 350000, China

Fujian Key Laboratory of Intelligent Imaging and Precision Radiotherapy for Tumors,  
Fujian Medical University

Clinical Research Center for Radiology and Radiotherapy of Fujian Province  
(Digestive, Hematological, and Breast Malignancies)

Tel: +86-13365910602

E-mail: benhuaxu@163.com

## Abstract

**Introduction:** Radiation-induced lung injury (RILI) is one of the most clinically-challenging toxicities and dose-limiting factors during and/or after thoracic radiation therapy for esophageal squamous cell carcinoma (ESCC). With limited effective protective drugs against RILI, the main strategy to reduce the injury is strict adherence to dose-volume restrictions of normal lungs. RILI can manifest as acute radiation pneumonitis (RP) with cellular injury, cytokine release, and cytokine recruitment to inflammatory infiltrate, and subsequent chronic radiation pulmonary fibrosis. Pirfenidone inhibits the production of inflammatory cytokines, scavenges free radicals, and reduces hydroxyproline and collagen formation. Hence, pirfenidone might be a promising drug for RILI prevention. This study aims to evaluate the efficacy and safety of pirfenidone in preventing RILI in patients with locally advanced ESCC receiving chemoradiotherapy.

**Methods and analysis:** This study is designed as a randomized, placebo-controlled, double-blinded, single-center phase 2 trial and will explore whether the addition of pirfenidone during concurrent chemoradiation therapy (CCRT) could prevent RILI in patients with locally advanced ESCC unsuitable for surgery. Eligible participants will be randomized at 1:1 to pirfenidone and placebo groups. The primary endpoint is the incidence of grade  $\geq 2$  RILI. Secondary endpoints include the incidence of any grade other than grade  $> 2$  RILI, time to RILI occurrence, changes in pulmonary function after CCRT, completion rate of CCRT, disease-free survival (DFS), and overall survival (OS). The follow-up period will be 1 year. In case the results meet the primary endpoint of this trial, a phase 3 multicenter trial with a larger sample size will be required to substantiate the evidence of the benefit of pirfenidone in RILI prevention.

### **Ethics and dissemination**

This study was approved by the Ethics Committee of Fujian Union Hospital (No. 2021YF001-02). The findings of the trial will be disseminated through peer-reviewed journals, and national and international conference presentations.

**Trial registration:** ChiCTR2100043032

### **Strengths and limitations of this study**

- This is the first randomized controlled trial to explore the efficacy and safety of pirfenidone in RILI prevention.
- It is a double-blinded trial where neither patients nor physicians will know the treatment allocation.
- It is a phase 2 trial performed at a single center.
- The dosage of radiation is usually inconsistent, with patients with unresectable patients receiving 50 Gy to 60 Gy, and cases in the process of downstaging receiving 40 Gy due to further option of surgical resection.

**Key words:** Pirfenidone; radiation-induced lung injury; prevention; esophageal squamous cell carcinoma; concurrent chemoradiation therapy; randomized controlled trial.

### **Introduction**

1  
2  
3 Esophageal cancer is the eighth most common cancer worldwide. Of the 477,900  
4 new cases reported globally per year, nearly half occur in China, and 90% of them are  
5 ESCC.<sup>1</sup> The definitive standard of care for unresectable locally advanced ESCC  
6 remains concurrent chemoradiation therapy, with a 3-year OS rate of 30%-37%.<sup>2-5</sup>  
7 Because the lungs often lay in the path of treatment radiation beams, radiation-induced  
8 lung injury (RILI) is inevitable. RILI is one of the most common side effects and  
9 potentially dose-limiting toxicities of radiotherapy for esophageal cancer, with an  
10 incidence of about 10.7%-35.14%.<sup>6-11</sup> Furthermore, RILI during radiation can delay or  
11 even interrupt radiotherapy, resulting in poor local control of the disease, increased  
12 financial burden, and even death.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

27 Although advanced radiotherapeutic technologies such as intensity-modulated  
28 radiation therapy (IMRT) are superior to traditional 2D and 3D conformal radiation  
29 therapies regarding dosimetry and organ protection,<sup>10 12</sup> many patients still develop  
30 varying degrees of RILI.<sup>13</sup> In clinical practice, there is no specific treatment for RILI  
31 except oxygen inhalation, glucocorticoid administration, and the application of  
32 antibiotics when necessary. Therefore, preventing RILI is of greater clinical  
33 significance than treating it. Although amifostine was approved by the US Food & Drug  
34 Administration (FDA) for radiotherapy protection, it does not efficiently protect against  
35 RILI during esophageal cancer treatment.<sup>14 15</sup> Moreover, its clinical application is  
36 limited because of high cost and frequent side effects. Therefore, few effective  
37 protective strategies against RILI during radiotherapy are available for patients with  
38 ESCC.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53

54 Pirfenidone is an active small-molecule oral drug that inhibits transforming growth  
55 factor (TGF)- $\beta$ 1 overexpression and reduces the secretion of platelet-derived growth  
56  
57  
58  
59  
60

1  
2  
3 factor (PDGF) and fibroblast growth factor (FGF), thereby suppressing the biological  
4 activity of fibroblasts.<sup>16-18</sup> Pharmacodynamic studies have demonstrated pirfenidone  
5 exerts satisfactory effects in lung inflammation and fibrosis.<sup>19-22</sup> The FDA approved  
6 pirfenidone in 2014 for the treatment of idiopathic pulmonary fibrosis (IPF),<sup>23 24</sup> which  
7 shares some pathological manifestations with RILI.<sup>25 26</sup> A previous study in mice  
8 showed pirfenidone attenuates RILI.<sup>27</sup> A phase 2 trial is in the recruitment stage and  
9 aims to confirm the efficacy of pirfenidone in the treatment of RILI (ClinicalTrials.gov  
10 NCT03902509).

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

There are no published clinical data to assess the prophylactic role of pirfenidone in RILI. Therefore, this randomized, placebo-controlled, double-blinded, single-center, phase 2 trial is designed to examine whether pirfenidone could reduce the occurrence of RILI in patients with locally advanced ESCC administered CCRT.

## Methods

### *Study design and participants*

This is a randomized, placebo-controlled, double-blinded, single-center, phase 2 clinical trial to examine the potential of pirfenidone in preventing RILI in patients with unresectable locally advanced ESCC at diagnosis administered CCRT. The participants will be randomized at 1:1 to the pirfenidone and control groups. Figure 1 depicts the overview of the study procedure.

The detailed inclusion, exclusion, and withdrawal criteria are listed in Table 1.

All eligible patients should provide written informed consent and be willing to participate in and complete the study, including follow-up.

### ***Pre-treatment assessment and screening***

Each patient must complete the following examinations and undergo counseling within 1 or 2 weeks before the onset of the trial:

- 1) Detailed medical history review.
- 2) Physical examinations to record height, weight, vital signs, and Eastern Cooperative Oncology Group (ECOG) performance status.
- 3) Blood tests, including complete blood count (CBC), serum biochemistry, coagulation function, hepatitis B virus (HBV) and HBV DNA (for HBsAg-positive patients), and esophageal cancer-related tumor markers such as carcinoembryonic antigen (CEA), cancer antigen (CA) 199, CA125, CA153, neuron-specific enolase (NSE), squamous cell carcinoma antigen (SCC), soluble fragment of cytokeratin 19 (Cyfra21-1), and  $\alpha$ -fetoprotein (AFP).
- 4) Cardiopulmonary function evaluation, including electrocardiography, ultrasonic cardiography, and pulmonary function assessment.
- 5) Upper gastrointestinal endoscopy and biopsy.
- 6) Imaging, including chest/abdominal computed tomography (CT) with intravenous contrast and upper gastrointestinal swallowed meglumine diatrizoate contrast, pelvic CT with contrast as clinically indicated, and [ $^{18}\text{F}$ ]fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) if accepted by the patient, leading to more accurate staging.
- 7) Nutritional assessment and counseling.
- 8) Smoking cessation counseling.

## ***Radiotherapy***

The target contour principle is as follows. Gross tumor volume (GTV) includes the primary tumor (GTVp) and enlarged regional lymph nodes (GTVn), determined by CT simulation scan and other diagnostic imaging methods. Elective node irradiation (ENI) will be used for clinical target volume (CTV) delineation. CTV of GTVp is defined as primary tumor volume plus a superior-inferior 3cm margin expansion and a 0.5-1-cm radial expansion including para-esophageal lymph nodes. CTV of GTVn will cover all the lymph nodes involved and high-risk lymphatic drainage regions such as the supraclavicular region for super-thoracic and middle-thoracic sections.<sup>28</sup> Planning target volume (PTV) for GTV and CTV will be created by expanding with a uniform margin of 0.5 cm separately. The recommended doses for PTV-CTV and PTV-GTV are 50.4 Gy/1.8 Gy/28 fractions and 60 Gy/1.8 Gy/33 fractions, respectively. If the target area is large and OAR cannot be achieved, only PTV-GTV irradiation or PTV-CTV irradiation can be performed as determined by the treating radiotherapist. The administered dose should cover at least 95% of the PTV. Normal tissue tolerance dose-limits are listed in Table 2. All patients will be positioned supine on the treatment couch and fixed with a custom-fitted thermoplastic sheet, and setup imaging will be acquired every day before treatment to correct the treatment position by the On-board imaging (OBI) image system. IMRT is recommended when the treatment plans are designed. Dose calculation for areas with artifacts generates heterogeneity, leading to high dose deviation. To ensure the quality of the radiotherapy delivered, the Acuros XB (version



1  
2  
3  
4 15.5) dose algorithm that was reported to be as accurate as or close to the Monte Carlo  
5  
6 (MC) simulation method will be employed in this present study. The treatment plan for  
7  
8 all patients will be verified using the Delta4 Phantom, and the gamma passing rate at  
9  
10 the criteria of 3%/3 mm will be greater than 98%.  
11  
12

13  
14 Resectability will be re-assessed by a multidisciplinary team at irradiation with  
15  
16 41.4 Gy. If surgical resection is possible, radiation therapy will be discontinued, and  
17  
18 surgery will be performed 4-8 weeks after radiation termination.  
19  
20

### 21 22 ***Chemotherapy*** 23

24  
25 The participants will receive docetaxel at 60 mg/m<sup>2</sup> intravenously on day 1 and  
26  
27 cisplatin at 30 mg/m<sup>2</sup> intravenously on days 1 and 2 for two cycles. Polyethylene glycol  
28  
29 recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) is  
30  
31 recommended for the prevention of neutropenia during CCRT. Dose modification will  
32  
33 be based on the preceding cycle's CBC data and biochemical markers. Chemotherapy  
34  
35 will be continued with: 1) absolute neutrophil count (ANC)  $\geq 1.5 \times 10^9/L$ ; 2) platelet  
36  
37 count  $\geq 100 \times 10^9/L$ ; 3) grade  $< 2$  alanine transaminase (ALT), aspartate transaminase  
38  
39 (AST), and total bilirubin based on Common Terminology Criteria for Adverse  
40  
41 Events (CTCAE) criteria; 4) non-hematological toxicity (except for hair loss)  
42  
43 returning to grade 1 or baseline level. The doses of both drugs will be decreased by 20%  
44  
45 in case of any grade 3 or higher toxicities. In case of grade 3 or 4 radiation pneumonitis,  
46  
47 radiotherapy and concurrent chemotherapy will be terminated.  
48  
49  
50  
51  
52

### 53 54 ***Randomization and intervention*** 55

56  
57 The participants will be randomized at 1:1 to the pifrenidone or control groups  
58  
59  
60

1  
2  
3 using a random number table and stratified based on tolerability or ineligibility to  
4 surgery. Participants and doctors will be blinded to treatment allocation. Identical  
5 pirfenidone and placebo capsules will be provided by Beijing Continent Pharmaceutical  
6 Co., Ltd. The appearance, smell, taste, and properties of the placebo are the same as  
7 those of the study drug. Each capsule contains 100 mg of drug or placebo. In the first  
8 week, the dosage will be 200 mg/time, 3 times/day. In the second week, the dosage will  
9 be increased to 300 mg/time, 3 times/day. In weeks 3-12, the dosage will be further  
10 increased to 400 mg/time, 3 times/day. Pirfenidone treatment will start on the day of  
11 radiotherapy initiation and last for 12 weeks. The capsules will be taken during or after  
12 meals as gastrointestinal reactions are the most common adverse effects of pirfenidone.  
13 Photosensitivity is another common adverse event. External use of sunscreen and  
14 avoiding the sun during medication can effectively reduce the incidence and severity of  
15 photosensitivity reactions. In case adverse events still occur or cannot be tolerated even  
16 after dose reduction, the drug will be temporarily discontinued for 1-2 weeks until the  
17 participant tolerates the symptoms. Once adverse events are alleviated or can be  
18 tolerated, the participant will retake pirfenidone. The physician can decide whether to  
19 stop the drug treatment according to the situation. Pirfenidone treatment will be  
20 permanently discontinued in case of severe adverse events, including liver dysfunction,  
21 jaundice, severe hypersensitivity, and photosensitivity.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

### 47 ***Concomitant medication***

48  
49  
50 Drugs that may prevent or treat fibrosis are forbidden, including amifostine and  
51 thalidomide. The participants should avoid the concurrent use of drugs that increase the  
52 adverse reactions of pirfenidone, including ciprofloxacin, amiodarone and propafenone.  
53  
54  
55  
56  
57 The participants should also avoid concurrent administration of medications that can  
58  
59  
60

1  
2  
3 reduce the efficacy of pirfenidone, including omeprazole and rifampin.  
4  
5

### 6 ***Endpoints*** 7 8

9 The primary endpoint is the incidence of grade 2 or higher RILI in the full analysis  
10 set (FAS) and per-protocol set (PPS). RILI will be evaluated according to CTCAE  
11 version 5.0.<sup>29</sup> within 1 year. Secondary endpoints include the incidence of RILI of any  
12 grade, time to RILI occurrence, pulmonary function changes after radiotherapy,  
13 completion rate of CCRT, DFS and OS.  
14  
15  
16  
17  
18  
19  
20  
21

22 RLIL is a diagnosis established based on clinical suspicion or radiological findings  
23 after excluding other lung pathologies such as pre-existing pathologies and pulmonary  
24 infection. It often occurs with no specific symptom, altered vital signs, laboratory  
25 profiling or imaging findings. The familiar history of radiation and recognition of RILI  
26 are of utmost importance in the context of regular follow-up. Diagnosis and grading  
27 will be confirmed after review by multidisciplinary senior physicians, including a  
28 radiation oncologist, a pulmonologist, and a radiologist. Medical history, physical  
29 parameters, chest CT scans, and previous radiotherapy will be evaluated at every  
30 follow-up during personal visits when available. RILI will be scored based on the  
31 CTCAE version 5.0 classifying symptoms and imaging findings will be used to classify  
32 into five grades<sup>29</sup> For symptoms, dyspnea and dry cough are the most common  
33 manifestations-in acute lung injury.<sup>30</sup> Occasional fever is usually mild, but high fever  
34 is sometimes reflective of co-infectious pneumonitis. Chronic radiation fibrosis (RF) is  
35 a slowly progressing respiratory disease that can manifest as respiratory insufficiency.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60 In terms of physical symptoms, physical examination findings may be normal or

1  
2  
3  
4 include pleural rub, moist rales, and signs of consolidation. Chest imaging, particular  
5  
6 lung CT at baseline and follow-up are critical in the diagnosis and grading. In the acute  
7  
8 phase, which usually appears 4-8 weeks after radiotherapy, CT images may display  
9  
10 exudative changes such as multiple small patchy or flock-shaped ground glass density  
11  
12 shadows in the irradiation field, with fuzzy edges and unclear boundaries with  
13  
14 surrounding lung tissue. In the consolidation phase, which usually occurs 2-3 months  
15  
16 after radiotherapy, CT images may display patchy high-density consolidations in the  
17  
18 irradiation field, not distributed according to the lung lobe or lung segment,  
19  
20 accompanied by partial air bronchial signs. In the fibrotic stage, which usually occurs  
21  
22 six months after radiotherapy, CT images may show density enhancement shadows of  
23  
24 grid, cord, or patchy shape in the irradiation field with clear boundaries, accompanied  
25  
26 by thickened pleura, lung volume reduction, lung hilum reduction, ipsilateral vascular  
27  
28 texture thinning, and compensatory increase in contralateral lung volume.<sup>31-35</sup>  
29  
30  
31  
32  
33  
34  
35  
36  
37

38  
39 Considering the anti-inflammatory and anti-fibrotic properties of pirfenidone, the  
40  
41 grade will be scored at the maximal level in cases who experience RP and RF. When  
42  
43 one case shows grade 3 RP and grade 2 RF, grade 3 will be recorded for the primary  
44  
45 endpoint. As pirfenidone is a promising drug for the prevention of RP and RF, we chose  
46  
47  
48  
49 1 year to observe the rates of RP and RF.  
50  
51  
52  
53

#### 54 ***Follow-up***

- 57 1. During the intervention period.

- 1) CBC and biochemical profiles will be verified once a week.
- 2) Physical examination and nutritional score assessment will be performed once a week.
- 3) Pulmonary function and chest/abdominal CT will be performed after 23 fractions to assess tumor regression and eligibility for surgery.

## 2. Post-treatment

The follow-up period will be 1 year or until death. All participants will be followed up at 1 month after radiotherapy and every 3 months thereafter, or as needed clinically. Routine follow-up will include the assessment of clinical symptoms, CBC and tumor markers, contrast-enhanced CT and upper gastrointestinal contrast, and pulmonary function evaluation. Repeated gastroscopy is recommended for the first year. In case of suspected recurrence, physical examination, radiography, and pathological examination will be performed.

### ***Statistical analysis***

Based on retrospective studies in the authors' hospital and literature reviews,<sup>7 8 36-38</sup> it is assumed that the occurrence rate of grade  $\geq 2$  RILI in the control group is 25%, versus 10% in the pirfenidone group. This trial is designed as a randomized phase 2 study with a two-sided  $\alpha$  of 0.20 and a power of 80%,<sup>39</sup> using the PASS software version 15.0.5 to calculate the sample size. From a phase 2 screening design, a higher  $\alpha$  level than 0.05 will be used for the next phase 3 design. Even if the phase 2 trial is successful, such a positive result is not usually considered to be definitive without a subsequent phase 3 trial. In this study, 36 participants will be included in each group with an  $\alpha$ -level of 0.2 and a power of 80%. Considering a dropout rate of 20%, it is planned to

1  
2  
3 enroll about 88 participants.  
4  
5

6 All analyses will be performed with SAS version 9.3 (SAS Institute, Cary, NC,  
7 USA). The t-test will be used for analyzing continuous data. The chi-square test and  
8 Fisher's exact probability method will be used for comparing categorical data. The  
9 survival rate will be calculated by the Kaplan-Meier method, and between-group  
10 comparisons will use the log-rank test. The confidence interval of the survival  
11 distribution will be calculated according to Greenwood's formula. A proportional  
12 hazard regression model for risk estimation will be used to derive hazard ratios.  $P < 0.05$   
13 will be considered statistically significant.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

#### 25 ***Data collection and management***

26 All clinical data will be collected by a research assistant and recorded in detail in  
27 the predesigned electronic table. All written informed consent forms will be stored in a  
28 separate closet, and only researchers would access the relevant research data. All study  
29 procedures were developed to ensure data protection and confidentiality.  
30  
31  
32  
33  
34  
35  
36

#### 37 ***Dissemination***

38 The results will be disseminated in international peer-reviewed conferences and  
39 journals.  
40  
41  
42  
43  
44

#### 45 ***Patient and public involvement***

46 Patients and the public are not involved in the design or execution of the study or  
47 the outcome measures.  
48  
49  
50  
51  
52

#### 53 **Discussion**

1  
2  
3  
4 For many years, radiotherapy (RT) has been employed for the treatment of  
5  
6 esophageal cancer as a curative or palliative measure. However, RILI is a common and  
7  
8 severe side effect of radiation, which can delay or interrupt antitumor therapy, resulting  
9  
10 in poor local control of the disease, decreased quality of life, and even death. Therefore,  
11  
12 prophylactic drugs to minimize toxicity and maximize efficacy in RT are required. To  
13  
14 date, the only FDA-approved cytoprotective agent is amifostine, but limited  
15  
16 effectiveness and significant side effects hamper its clinical application.<sup>14, 15, 34, 35</sup>  
17  
18 Consequently, pharmaceutical agents that are clinically applicable, especially for the  
19  
20 prevention of RILI are being developed<sup>40-42</sup> Pirfenidone is a small-molecule  
21  
22 biosynthetic drug with anti-inflammatory, anti-fibrotic, and antioxidant properties,<sup>16-18</sup>  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
43 which was approved by the FDA for the management of IPF.<sup>23 24 44-46</sup> As RILI has  
similar pathogenesis and clinical manifestations as IPF, characterized by inflammatory  
cell infiltration, interstitial edema, and interstitial fibrosis of the alveolar wall,<sup>26</sup>  
pirfenidone may hold promise for the prevention and treatment of RILI, which has been  
tested in preclinical and pilot studies.<sup>47, 27, 48, 49</sup> Currently, a multicenter phase II study  
on the treatment of RILI with pirfenidone is ongoing (NCT03902509), but no clinical  
study on the prevention has been reported. This is the first phase II study designed to  
explore the efficacy of pirfenidone in RILI prevention.

Most published data on RILI were derived from lung cancer. However, differences  
in anatomy, pathogenesis, and treatment between lung and esophageal tumors limit the  
extrapolation of RP prediction models for pulmonary tumors to esophageal tumors.  
This preliminary study was designed to focus on thoracic ESCC. Additionally, from the

1  
2  
3  
4 current NCCN guidelines and expert recommendations, tolerance dose-limits for the  
5  
6 lung vary from  $V20 \leq 20\%$  for esophageal and esophagogastric junction cancers, and  
7  
8  $V20 \leq 35\%-40\%$  for non-small cell lung cancer. Obviously, esophageal cancer has more  
9  
10 stringent restrictions on  $V20$ , which can be achieved by esophageal adenocarcinoma  
11  
12 (EA) treatment plan, since it is mainly present in the lower thoracic area in European  
13  
14 and American countries. But esophageal squamous cell carcinoma (ESCC),<sup>50 51</sup> highly  
15  
16 prevalent in China and other Asian countries, is often located in the upper or middle  
17  
18 esophagus. Therefore, compared to EA cases in whom the RT area is close to the  
19  
20 abdomen and the lung is relatively well protected, patients with thoracic ESCC are at  
21  
22 higher risk of lung exposure and may require particular attention.<sup>52</sup> Consequently, the  
23  
24 recommended tolerance dose-limits of the lung are  $V20 \leq 28-30\%$ ,  $V5 \leq 60\%$ , and mean  
25  
26 lung dose ( MLD )  $< 15 \text{ Gy}$ <sup>53</sup> in the present study.  
27  
28  
29  
30  
31  
32  
33  
34

35 The estimated incidence of RILI varies widely across esophageal cancer studies  
36  
37 from 3.33% to 35% for grade 2 lung injury, and 0% to 21% for grade 3 lung injury. It  
38  
39 is likely due to variations of target delineation, radiation dose, radiotherapy  
40  
41 techniques,<sup>10-12 36 54-58</sup> and classification systems. Since consensus on the optimal  
42  
43 radiation strategy for nodal irradiation is lacking and the accuracy of imaging diagnosis  
44  
45 is insufficient,<sup>59</sup> FDG-PET/CT at diagnosis is strongly recommended. Further, ENI is  
46  
47 adopted depending on the location of the primary tumor. Although the dose of 50 Gy  
48  
49 is the standard for CCRT in most Western countries, 60 Gy using modern radiation  
50  
51 technologies is preferred by clinicians in Asian countries based on the belief that 50 Gy  
52  
53 may not be enough for ESCC.<sup>53 60 61</sup> Consequently, 60 Gy for PTV-GTV and 50.4 Gy  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4 for PTV-CTV will be administered in the present study. However, only PTV-GTV or  
5  
6 PTV-CTV irradiation is allowed when normal tissue constraints cannot be met by  
7  
8 therapy, which is decided by the physician. Additionally, due to the anatomical features  
9  
10 of the esophagus, including the lack of serosa and the presence of numerous  
11  
12 surrounding organs, most patients in this trial have cT4N+M0 thoracic esophageal  
13  
14 cancer. Until now, a standard treatment option for cT4N+M0 thoracic esophageal  
15  
16 cancer has not been established, and therefore, definitive chemoradiotherapy (CRT) or  
17  
18 chemoradiotherapy plus conversional surgery for downstaging are both accepted  
19  
20 treatments.<sup>61</sup> The major difference between neoadjuvant and definitive CRT is the  
21  
22 radiation dose (41.4 Gy vs. 50-60 Gy), which is the most crucial factor affecting the  
23  
24 development of RILI. For this reason, stratified random cluster sampling will be applied  
25  
26 for balancing the two groups.  
27  
28  
29  
30  
31  
32  
33  
34

35 Considering anti-inflammatory and anti-fibrotic properties<sup>16-18 43</sup>, the incidence of  
36  
37 grade 2 or higher RILI is the primary endpoint to test in the prevention of symptomatic  
38  
39 RP and RF. The diagnosis of RILI is challenging due to differential or concomitant  
40  
41 diseases such as infections and exacerbation of pre-existing pulmonary conditions.  
42  
43 Particularly, in some cases pneumonia patches in the radiation beam pathway as well  
44  
45 as RP complicated with infectious pneumonia could not be identified.<sup>58</sup> In addition, RP  
46  
47 grading is limited by subjectivity, especially in diagnosing grade 2 and grade 3.  
48  
49 Therefore, the classification will be confirmed by a board-certified radiation oncologist  
50  
51 referring to a joint expert consultation. The multidisciplinary team consists of a senior  
52  
53 radiation oncologist, a pulmonologist, and a radiologist with broad experience in RILI.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 In summary, the present study design attempted to control for most of the  
4 important risk factors for RILI as described above. The results might provide new  
5 options for the prevention of RILI. However, owing to the limited sample size, further  
6 research is required to substantiate the efficacy of pirfenidone in the prevention of RILI  
7 using a multicenter phase 3 trial with a larger sample size.  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17

### 18 **List of abbreviations**

19  
20  
21 AE, adverse event; AFP,  $\alpha$ -fetoprotein; ALT, alanine transaminase; ANC, absolute  
22 neutrophil count; AST, aspartate transaminase; CA, cancer antigen; CBC, complete  
23 blood counts; CCr, creatinine clearance rate; CCRT, concurrent chemoradiation  
24 therapy; CEA, carcinoembryonic antigen; CRT, chemoradiotherapy; CT, computed  
25 tomography; CTCAE, Common Terminology Criteria for Adverse Events; CTV,  
26 clinical target volume; Cyfra21-1, soluble fragment of cytokeratin 1; DFS, disease-free  
27 survival; Dmax, maximal dose; EA, esophageal adenocarcinoma; ECOG, Eastern  
28 Cooperative Oncology Group; ENI, elective node irradiation; ESCC, esophageal  
29 squamous cell carcinoma; FAS : full analysis set; FDG-PET/CT : [18F]  
30 fluorodeoxyglucose positron emission tomography/computed; FGF, fibroblast growth  
31 factor; FDA, Food & Drug Administration; GTV, gross tumor volume; HBV, hepatitis  
32 B virus; IL, interleukin; IMRT, intensity-modulated radiation therapy; IPF, idiopathic  
33 pulmonary fibrosis; MC, Monte Carlo; MLD, mean lung dose; NRS, nutritional risk  
34 scale; NSE, neuron-specific enolase; OAR, organs at risk; OBI, On-board imaging; OS,  
35 overall survival; PDGF, platelet-derived growth factor; PEG-rhG-CSF, Polyethylene  
36 glycol recombinant human granulocyte colony-stimulating factor; PPS: per-protocol  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 set; PTV, planned target volume; RF, radiation fibrosis; RILI, radiation-induced lung  
4  
5 injury; RP, radiation pneumonitis; RT, radiotherapy; SCC, squamous cell carcinoma  
6  
7 antigen; SCr, serum creatinine; TGF, tumor growth factor; TNF, tumor necrosis factor;  
8  
9 ULN, upper limit of normal; WBC, white blood cells.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Acknowledgements

We thank all the patients who will participate in this trial and all participating doctors and investigators who devoted their time and passion to the implementation of this study. We are grateful to Xiaobo Li and Jianping Zhang for their contribution to the revision of the manuscript. We thank Beijing Continent Pharmaceutical Co., Ltd. for providing both the pirfenidone and placebo capsules.

## Authors' contributions

XBH, the principal investigator responsible for the study design, also revised the article critically and approved the final version to be published. CC mainly participated in protocol design and writing. ZBW and YY were responsible for statistical analysis and study design. CC and KMQ were responsible for surgery recommendation. XD, CRX, LSQ and ZHL made substantial contributions to the design of the study. All authors read and approved the final manuscript.

## Funding

The pirfenidone and placebo are provided by Beijing Continent Pharmaceuticals Co., Ltd. (no grant number). The study was funded by the Fourth Batch of Hospital Key Discipline Construction Program of Fujian Medical University Union Hospital (No. 2021FLK01KY). The funders had no roles in study design; data collection, analysis, and interpretation; writing of the report; or the decision to submit the paper for publication.

## Competing interest statement

All authors declare that they have no competing interests.

1  
2  
3 **Consent for publication**  
4  
5

6 Not applicable.  
7  
8

9 **Ethics approval and consent to participate**  
10

11  
12 The study protocol was approved by the Ethics Committee of Fujian Union Hospital  
13  
14 (No. 2021YF001-02). Signed informed consent from each participant is required. The  
15  
16 trial was registered in chictr.org.cn (ChiCTR2100043032).  
17  
18

19 **Provenance and peer review**  
20

21  
22 Not commissioned; externally peer reviewed.  
23  
24

25 **Data availability statement**  
26

27  
28 Not applicable – data collection is still ongoing.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. *CA Cancer J Clin* 2015;65(2):87-108. doi: 10.3322/caac.21262 [published Online First: 2015/02/06]
2. Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. *N Engl J Med* 1992;326(24):1593-8. doi: 10.1056/NEJM199206113262403 [published Online First: 1992/06/11]
3. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. *JAMA* 1999;281(17):1623-7. doi: 10.1001/jama.281.17.1623 [published Online First: 1999/05/11]
4. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. *J Clin Oncol* 2002;20(5):1167-74. doi: 10.1200/JCO.2002.20.5.1167 [published Online First: 2002/03/01]
5. Li QQ, Liu MZ, Hu YH, et al. Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma. *Dis Esophagus*

- 2010;23(3):253-9. doi: 10.1111/j.1442-2050.2009.01003.x [published Online First: 2009/09/08]
6. Du F, Wang Q, Wang W, et al. Analysis of related factors of radiation pneumonitis after radiotherapy for thoracic segment esophageal cancer. *Zhong Hua Fang She Yi Xue Yu Fang Hu Za Zhi* 2020;40(11):832–39.
7. Cao Y, Shen W, Zhu S. Low Dose Volume of Lung in Predicting Acute Radiation Pneumonitis in Patients with Middle and Lower Thoracic Esophageal Cancer. *Zhong Liu Fang Zhi Yan Jiu* 2015;0(1):32–36.
8. Zhen L, Zhao S, Xu C, et al. Clinical and dosimetric factors associated with acute radiation-induced pneumonitis in esophageal carcinoma patients after intensity modulated radiation therapy (IMRT). *Zhen Duan Xue Li Lun Yu Shi Jian* 2019;0(1):66–71.
9. Wu W, Tan Y, Xiao N, et al. Analysis of influencing factors of radiation-induced lung injury in patients with esophageal cancer treated by IMRT. *Tian Jin Yi Yao* 2019;0(2):159–62.
10. Fu WH, Wang LH, Zhou ZM, et al. Comparison of conformal and intensity-modulated techniques for simultaneous integrated boost radiotherapy of upper esophageal carcinoma. *World J Gastroenterol* 2004;10(8):1098-102. doi: 10.3748/wjg.v10.i8.1098 [published Online First: 2004/04/08]
11. Wang L, Liang S, Li C, et al. A Novel Nomogram and Risk Classification System

- 1  
2  
3  
4 Predicting Radiation Pneumonitis in Patients With Esophageal Cancer  
5  
6 Receiving Radiation Therapy. *Int J Radiat Oncol Biol Phys* 2019;105(5):1074-  
7  
8 85. doi: 10.1016/j.ijrobp.2019.08.024 [published Online First: 2019/08/29]  
9  
10  
11  
12 12. Chandra A, Guerrero TM, Liu HH, et al. Feasibility of using intensity-modulated  
13  
14 radiotherapy to improve lung sparing in treatment planning for distal esophageal  
15  
16 cancer. *Radiother Oncol* 2005;77(3):247-53. doi:  
17  
18 10.1016/j.radonc.2005.10.017 [published Online First: 2005/11/22]  
19  
20  
21  
22  
23 13. Shen W, Xu J, Li S, et al. Prognostic analysis of intensity-modulated radiotherapy  
24  
25 for cervical and upper thoracic esophageal carcinoma. *Zhong Hua Fang She*  
26  
27 *Zhong Liu Xue Za Zhi* 2020;29(10):842-48.  
28  
29  
30  
31  
32 14. Orditura M, De Vita F, Belli A, et al. Efficacy and safety profile of amifostine in  
33  
34 the preoperative combined therapy of esophageal cancer patients. *Oncol Rep*  
35  
36 2000;7(2):397-400. doi: 10.3892/or.7.2.397 [published Online First:  
37  
38 2000/02/15]  
39  
40  
41  
42  
43 15. Jatoi A, Martenson JA, Foster NR, et al. Paclitaxel, carboplatin, 5-fluorouracil, and  
44  
45 radiation for locally advanced esophageal cancer: phase II results of preliminary  
46  
47 pharmacologic and molecular efforts to mitigate toxicity and predict outcomes:  
48  
49 North Central Cancer Treatment Group (N0044). *Am J Clin Oncol*  
50  
51 2007;30(5):507-13. doi: 10.1097/COC.0b013e31805c139a [published Online  
52  
53 First: 2007/10/09]  
54  
55  
56  
57  
58  
59  
60



- 1  
2  
3  
4 16. Oku H, Nakazato H, Horikawa T, et al. Pirfenidone suppresses tumor necrosis  
5  
6 factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock.  
7  
8  
9 *Eur J Pharmacol* 2002;446(1-3):167-76. doi: 10.1016/s0014-2999(02)01757-0  
10  
11 [published Online First: 2002/07/06]  
12  
13  
14  
15 17. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on procollagen gene  
16  
17 expression at the transcriptional level in bleomycin hamster model of lung  
18  
19 fibrosis. *J Pharmacol Exp Ther* 1999;289(1):211-8. [published Online First:  
20  
21 1999/03/23]  
22  
23  
24  
25  
26 18. Misra HP, Rabideau C. Pirfenidone inhibits NADPH-dependent microsomal lipid  
27  
28 peroxidation and scavenges hydroxyl radicals. *Mol Cell Biochem* 2000;204(1-  
29  
30 2):119-26. doi: 10.1023/a:1007023532508 [published Online First: 2000/03/16]  
31  
32  
33  
34  
35 19. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming  
36  
37 growth factor-beta gene expression at the transcriptional level in bleomycin  
38  
39 hamster model of lung fibrosis. *J Pharmacol Exp Ther* 1999;291(1):367-73.  
40  
41 [published Online First: 1999/09/22]  
42  
43  
44  
45  
46 20. Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits PDGF isoforms  
47  
48 in bleomycin hamster model of lung fibrosis at the translational level. *Am J*  
49  
50 *Physiol* 1999;276(2):L311-8. doi: 10.1152/ajplung.1999.276.2.L311 [published  
51  
52 Online First: 1999/02/10]  
53  
54  
55  
56  
57 21. Iyer SN, Wild JS, Schiedt MJ, et al. Dietary intake of pirfenidone ameliorates  
58  
59  
60

- 1  
2  
3  
4 bleomycin-induced lung fibrosis in hamsters. *J Lab Clin Med* 1995;125(6):779-  
5  
6  
7 85. [published Online First: 1995/06/01]  
8  
9  
10 22. Kehrer JP, Margolin SB. Pirfenidone diminishes cyclophosphamide-induced lung  
11  
12 fibrosis in mice. *Toxicol Lett* 1997;90(2-3):125-32. doi: 10.1016/s0378-  
13  
14 4274(96)03845-3 [published Online First: 1997/02/07]  
15  
16  
17  
18 23. Margaritopoulos GA, Trachalaki A, Wells AU, et al. Pirfenidone improves survival  
19  
20 in IPF: results from a real-life study. *BMC Pulm Med* 2018;18(1):177. doi:  
21  
22 10.1186/s12890-018-0736-z [published Online First: 2018/11/25]  
23  
24  
25  
26 24. Adams TN, Eiswirth C, Newton CA, et al. Pirfenidone for Idiopathic Pulmonary  
27  
28 Fibrosis. *Am J Respir Crit Care Med* 2016;194(3):374-6. doi:  
29  
30 10.1164/rccm.201602-0258RR [published Online First: 2016/06/01]  
31  
32  
33  
34 25. Ying HJ, Fang M, Chen M. Progress in the mechanism of radiation-induced lung  
35  
36 injury. *Chin Med J (Engl)* 2020;134(2):161-63. doi:  
37  
38 10.1097/CM9.0000000000001032 [published Online First: 2020/09/06]  
39  
40  
41  
42  
43 26. Turkkan G, Willems Y, Hendriks LEL, et al. Idiopathic pulmonary fibrosis: Current  
44  
45 knowledge, future perspectives and its importance in radiation oncology.  
46  
47 *Radiother Oncol* 2021;155:269-77. doi: 10.1016/j.radonc.2020.11.020  
48  
49 [published Online First: 2020/11/28]  
50  
51  
52  
53  
54 27. Qin W, Liu B, Yi M, et al. Antifibrotic Agent Pirfenidone Protects against  
55  
56 Development of Radiation-Induced Pulmonary Fibrosis in a Murine Model.  
57  
58  
59  
60

- 1  
2  
3  
4 *Radiat Res* 2018;190(4):396-403. doi: 10.1667/RR15017.1 [published Online  
5  
6 First: 2018/07/18]  
7  
8  
9
- 10 28. National Comprehensive Cancer Network. Esophageal and Esophagogastric  
11  
12 Junction Cancers (version 3.2021).  
13  
14
- 15 29. USDOHAH S. Common Terminology Criteria for Adverse Events (CTCAE) 2017.  
16  
17 Available from:  
18  
19 [27](https://ctepcancer.gov/protocolDevelopment/electronic_applications/docs/CTC<br/>20<br/>21 <u>AE_v5_Quick_Reference_85x11.pdf</u>.<br/>22<br/>23<br/>24<br/>25</a></p><p>26 30. Rodrigues G, Lock M, D'Souza D, et al. Prediction of radiation pneumonitis by dose<br/>27<br/>28 - volume histogram parameters in lung cancer--a systematic review.<br/>29<br/>30 <i>Radiotherapy and oncology : journal of the European Society for Therapeutic<br/>31<br/>32 Radiology and Oncology</i> 2004;71(2):127-38. doi:<br/>33<br/>34 10.1016/j.radonc.2004.02.015 [published Online First: 2004/04/28]<br/>35<br/>36<br/>37<br/>38<br/>39</p><p>40 31. Larici AR, del Ciello A, Maggi F, et al. Lung abnormalities at multimodality<br/>41<br/>42 imaging after radiation therapy for non-small cell lung cancer. <i>Radiographics :</i><br/>43<br/>44 <i>a review publication of the Radiological Society of North America, Inc</i><br/>45<br/>46 2011;31(3):771-89. doi: 10.1148/rg.313105096 [published Online First:<br/>47<br/>48 2011/05/17]<br/>49<br/>50<br/>51<br/>52<br/>53</p><p>54 32. Choi YW, Munden RF, Erasmus JJ, et al. Effects of radiation therapy on the lung:<br/>55<br/>56 radiologic appearances and differential diagnosis. <i>Radiographics : a review</i><br/>57<br/>58<br/>59<br/>60</p></div><div data-bbox=)

- 1  
2  
3  
4 *publication of the Radiological Society of North America, Inc* 2004;24(4):985-  
5  
6 97; discussion 98. doi: 10.1148/rg.244035160 [published Online First:  
7  
8 2004/07/17]  
9  
10  
11  
12 33. Yamashita H, Takahashi W, Haga A, et al. Radiation pneumonitis after stereotactic  
13  
14 radiation therapy for lung cancer. *World journal of radiology* 2014;6(9):708-15.  
15  
16 doi: 10.4329/wjr.v6.i9.708 [published Online First: 2014/10/03]  
17  
18  
19  
20  
21 34. Linda A, Trovo M, Bradley JD. Radiation injury of the lung after stereotactic body  
22  
23 radiation therapy (SBRT) for lung cancer: a timeline and pattern of CT changes.  
24  
25 *European journal of radiology* 2011;79(1):147-54. doi:  
26  
27 10.1016/j.ejrad.2009.10.029 [published Online First: 2009/12/04]  
28  
29  
30  
31  
32 35. Ghaye B, Wanet M, El Hajjam M. Imaging after radiation therapy of thoracic  
33  
34 tumors. *Diagnostic and interventional imaging* 2016;97(10):1037-52. doi:  
35  
36 10.1016/j.diii.2016.06.019 [published Online First: 2016/08/29]  
37  
38  
39  
40  
41 36. Asakura H, Hashimoto T, Zenda S, et al. Analysis of dose-volume histogram  
42  
43 parameters for radiation pneumonitis after definitive concurrent  
44  
45 chemoradiotherapy for esophageal cancer. *Radiother Oncol* 2010;95(2):240-4.  
46  
47 doi: 10.1016/j.radonc.2010.02.006 [published Online First: 2010/03/13]  
48  
49  
50  
51  
52 37. Ishida K, Ando N, Yamamoto S, et al. Phase II study of cisplatin and 5-fluorouracil  
53  
54 with concurrent radiotherapy in advanced squamous cell carcinoma of the  
55  
56 esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical  
57  
58  
59  
60

- 1  
2  
3  
4 Oncology Group trial (JCOG9516). *Jpn J Clin Oncol* 2004;34(10):615-9. doi:  
5  
6 10.1093/jjco/hyh107 [published Online First: 2004/12/14]  
7  
8  
9  
10 38. chen C, Zeng B, Xue D. Preliminary report of pirfenidone for the prevention of  
11  
12 radiation pneumonitis in patients with esophageal cancer: analysis using inverse  
13  
14 probability of treatment weighting[J]. *Chin J Clin Oncol* 2021;48(15):772-76.  
15  
16  
17  
18 39. Rubinstein LV, Korn EL, Freidlin B, et al. Design issues of randomized phase II  
19  
20 trials and a proposal for phase II screening trials. *J Clin Oncol*  
21  
22 2005;23(28):7199-206. doi: 10.1200/JCO.2005.01.149 [published Online First:  
23  
24 2005/09/30]  
25  
26  
27  
28  
29 40. Ozturk B, Egehan I, Atavci S, et al. Pentoxifylline in prevention of radiation-  
30  
31 induced lung toxicity in patients with breast and lung cancer: a double-blind  
32  
33 randomized trial. *International journal of radiation oncology, biology, physics*  
34  
35 2004;58(1):213-9. doi: 10.1016/s0360-3016(03)01444-5 [published Online  
36  
37 First: 2003/12/31]  
38  
39  
40  
41  
42  
43 41. Ghosh SN, Zhang R, Fish BL, et al. Renin-Angiotensin system suppression  
44  
45 mitigates experimental radiation pneumonitis. *International journal of*  
46  
47 *radiation oncology, biology, physics* 2009;75(5):1528-36. doi:  
48  
49 10.1016/j.ijrobp.2009.07.1743 [published Online First: 2009/11/26]  
50  
51  
52  
53  
54 42. Kharofa J, Cohen EP, Tomic R, et al. Decreased risk of radiation pneumonitis with  
55  
56 incidental concurrent use of angiotensin-converting enzyme inhibitors and  
57  
58  
59  
60

- 1  
2  
3  
4 thoracic radiation therapy. *International journal of radiation oncology, biology,*  
5  
6  
7 *physics* 2012;84(1):238-43. doi: 10.1016/j.ijrobp.2011.11.013 [published  
8  
9 Online First: 2012/02/04]  
10  
11  
12 43. Nakazato H, Oku H, Yamane S, et al. A novel anti-fibrotic agent pirfenidone  
13  
14 suppresses tumor necrosis factor-alpha at the translational level. *Eur J*  
15  
16 *Pharmacol* 2002;446(1-3):177-85. doi: 10.1016/s0014-2999(02)01758-2  
17  
18 [published Online First: 2002/07/06]  
19  
20  
21  
22  
23 44. Troy LK, Corte TJ. Therapy for idiopathic pulmonary fibrosis: lessons from pooled  
24  
25 data analyses. *Eur Respir J* 2016;47(1):27-30. doi: 10.1183/13993003.01669-  
26  
27 2015 [published Online First: 2016/01/02]  
28  
29  
30  
31  
32 45. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone for idiopathic pulmonary  
33  
34 fibrosis: analysis of pooled data from three multinational phase 3 trials. *Eur*  
35  
36 *Respir J* 2016;47(1):243-53. doi: 10.1183/13993003.00026-2015 [published  
37  
38 Online First: 2015/12/10]  
39  
40  
41  
42  
43 46. King TE, Jr., Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone  
44  
45 in patients with idiopathic pulmonary fibrosis. *N Engl J Med*  
46  
47 2014;370(22):2083-92. doi: 10.1056/NEJMoa1402582 [published Online First:  
48  
49 2014/05/20]  
50  
51  
52  
53  
54 47. Ji W, Jiang Y, Yang W, et al. Pirfenidone in prevention and treatment of radiation  
55  
56 pulmonary fibrosis. *Zhong Hua Fang She Zhong Liu Xue Za Zhi* 2010;6:560-  
57  
58  
59  
60

- 1  
2  
3  
4 63.  
5  
6  
7  
8 48. Sun YW, Zhang YY, Ke XJ, et al. Pirfenidone prevents radiation-induced intestinal  
9  
10 fibrosis in rats by inhibiting fibroblast proliferation and differentiation and  
11  
12 suppressing the TGF-beta1/Smad/CTGF signaling pathway. *Eur J Pharmacol*  
13  
14 2018;822:199-206. doi: 10.1016/j.ejphar.2018.01.027 [published Online First:  
15  
16 2018/01/29]  
17  
18  
19  
20  
21 49. Simone NL, Soule BP, Gerber L, et al. Oral pirfenidone in patients with chronic  
22  
23 fibrosis resulting from radiotherapy: a pilot study. *Radiat Oncol* 2007;2:19. doi:  
24  
25 10.1186/1748-717X-2-19 [published Online First: 2007/06/02]  
26  
27  
28  
29 50. Rustgi AK, El-Serag HB. Esophageal carcinoma. *The New England journal of*  
30  
31 *medicine* 2014;371(26):2499-509. doi: 10.1056/NEJMra1314530 [published  
32  
33 Online First: 2014/12/30]  
34  
35  
36  
37  
38 51. Arnold M, Ferlay J, van Berge Henegouwen MI, et al. Global burden of oesophageal  
39  
40 and gastric cancer by histology and subsite in 2018. *Gut* 2020;69(9):1564-71.  
41  
42 doi: 10.1136/gutjnl-2020-321600 [published Online First: 2020/07/02]  
43  
44  
45  
46 52. Stiles BM, Altorki NK. The NeoRes trial: questioning the benefit of radiation  
47  
48 therapy as part of neoadjuvant therapy for esophageal adenocarcinoma. *Journal*  
49  
50 *of thoracic disease* 2017;9(10):3465-68. doi: 10.21037/jtd.2017.08.146  
51  
52 [published Online First: 2017/12/23]  
53  
54  
55  
56  
57 53. National Health Commission Of The People's Republic Of C. Chinese guidelines  
58  
59  
60

- 1  
2  
3  
4 for diagnosis and treatment of esophageal carcinoma 2018 (English version).  
5  
6 *Chinese journal of cancer research = Chung-kuo yen cheng yen chiu*  
7  
8  
9 2019;31(2):223-58. doi: 10.21147/j.issn.1000-9604.2019.02.01 [published  
10  
11  
12 Online First: 2019/06/04]  
13  
14  
15 54. Ishikura S, Nihei K, Ohtsu A, et al. Long-term toxicity after definitive  
16  
17 chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus.  
18  
19 *Journal of clinical oncology : official journal of the American Society of*  
20  
21 *Clinical Oncology* 2003;21(14):2697-702. doi: 10.1200/jco.2003.03.055  
22  
23 [published Online First: 2003/07/16]  
24  
25  
26  
27  
28 55. Suntharalingam M, Winter K, Ilson D, et al. Effect of the Addition of Cetuximab to  
29  
30 Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal  
31  
32 Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial.  
33  
34 *JAMA oncology* 2017;3(11):1520-28. doi: 10.1001/jamaoncol.2017.1598  
35  
36  
37 [published Online First: 2017/07/09]  
38  
39  
40  
41  
42 56. Shi Z, Foley KG, Pablo de Mey J, et al. External Validation of Radiation-Induced  
43  
44 Dyspnea Models on Esophageal Cancer Radiotherapy Patients. *Frontiers in*  
45  
46 *oncology* 2019;9:1411. doi: 10.3389/fonc.2019.01411 [published Online First:  
47  
48 2020/01/11]  
49  
50  
51  
52  
53 57. Tonison JJ, Fischer SG, Viehrig M, et al. Radiation Pneumonitis after Intensity-  
54  
55 Modulated Radiotherapy for Esophageal Cancer: Institutional Data and a  
56  
57 Systematic Review. *Scientific reports* 2019;9(1):2255. doi: 10.1038/s41598-  
58  
59  
60



018-38414-5 [published Online First: 2019/02/21]

58. Hsieh HY, Yeh HL, Hsu CP, et al. Feasibility of intensity-modulated radiotherapy for esophageal cancer in definite chemoradiotherapy. *Journal of the Chinese Medical Association* : *JCMA* 2016;79(7):375-81. doi: 10.1016/j.jcma.2016.01.013 [published Online First: 2016/04/09]
59. Akiyama H, Tsurumaru M, Udagawa H, et al. Radical lymph node dissection for cancer of the thoracic esophagus. *Annals of surgery* 1994;220(3):364-72; discussion 72-3. doi: 10.1097/00000658-199409000-00012 [published Online First: 1994/09/01]
60. Zhang W, Luo Y, Wang X, et al. Dose-escalated radiotherapy improved survival for esophageal cancer patients with a clinical complete response after standard-dose radiotherapy with concurrent chemotherapy. *Cancer management and research* 2018;10:2675-82. doi: 10.2147/cmar.S160909 [published Online First: 2018/08/28]
61. Kuwano H, Nishimura Y, Oyama T, et al. Guidelines for Diagnosis and Treatment of Carcinoma of the Esophagus April 2012 edited by the Japan Esophageal Society. *Esophagus* : *official journal of the Japan Esophageal Society* 2015;12(1):1-30. doi: 10.1007/s10388-014-0465-1 [published Online First: 2015/01/27]

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Figure legends**

**Figure 1.** Flowchart of the study procedure.

For peer review only

**Table 1.** Inclusion, exclusion and withdrawal criteria.

Inclusion criteria	Exclusion criteria	Withdrawal criteria
<ul style="list-style-type: none"> <li>● Age between 18 and 75 years old.</li> <li>● ECOG performance status of 0-1.</li> <li>● Pathological confirmation of ESCC.</li> <li>● Imaging staging suggesting T<sub>3-4</sub>N+M0 thoracic esophageal cancer according to AJCC 8 staging criteria (primary lesions mainly in the chest cavity).</li> <li>● No restriction on the number of regional nodal stations or bulk of disease.</li> <li>● No ability to tolerate surgery or tumor not surgically removable.</li> </ul>	<ul style="list-style-type: none"> <li>● History of chest radiotherapy.</li> <li>● Concomitant tumor in other organs or prior malignancies within 5 years.</li> <li>● History of interstitial lung disease or non-infectious pneumonia including COPD.</li> <li>● Severe cardiovascular disease, cerebrovascular complications, epilepsy, active peptic ulcers, infections, psychological disorders, or other serious underlying diseases</li> </ul>	<ul style="list-style-type: none"> <li>● Treatment delay for more than 2 weeks or interruption due to extended toxicity.</li> <li>● Disease progression as judged by researchers during the treatment.</li> </ul>

- 
- No perforation or deep niche in the esophageal cancer lesion.
  - No prior chemotherapy, immunotherapy, or surgery before radiotherapy.
  - Ability to eat liquid foods.
  - Adequate bone marrow, liver, kidney, blood coagulation, and lung functions.
  - Life expectancy of >6 months.
  - Voluntary participation in the study, with good compliance.
- that may limit the patient's understanding and tolerance of comprehensive treatments.
  - A previous history of ataxia due to telangiectasia or other radiosensitivity reaction.
  - Scleroderma or active connective tissue disease.

---

ECOG, Eastern Cooperative Oncology Group; ESCC, esophageal squamous cell carcinoma; AJCC, American Joint Committee on Cancer; CT, computed tomography.

**Table 2.** Dose limits for organs at risk (OAR)

OAR	Normal Tissue Dose-Volume Constraints
Lung	V20 $\leq$ 28%-30%, V5 $\leq$ 60%; MLD <15 Gy
Heart	V40 <30%, V40 $\leq$ 30%; Mean $\leq$ 30 Gy
Spinal cord	Max $\leq$ 45 Gy
Stomach	V40 <40%, Max $\leq$ 55-60 Gy
Liver	V30 <40%; Mean $\leq$ 25 Gy

Vxx, % of the whole OAR receiving  $\geq$ xx Gy. MLD, mean lung dose

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1. Study flowchart.

170x194mm (300 x 300 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Page No
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
	2b	All items from the World Health Organization Trial Registration Data Set	3
Protocol version	3	Date and version identifier	/
Funding	4	Sources and types of financial, material, and other support	13
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1,2,13
	5b	Name and contact information for the trial sponsor	/
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	13,14
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	13,14
<b>Introduction</b>			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	3-4
	6b	Explanation for choice of comparators	4
Objectives	7	Specific objectives or hypotheses	5

Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	5
<b>Methods: Participants, interventions, and outcomes</b>			
Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	5
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	5, Table 1
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	6-8
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	8
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	8
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	8
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	9
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	5-9, Figure 1
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	10
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	/
<b>Methods: Assignment of interventions (for controlled trials)</b>			
Allocation:			



Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	8
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	8
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	/
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	8
	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	/
<b>Methods: Data collection, management, and analysis</b>			
Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	5-6,9
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	9
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	10
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	10
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	/
	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	10

<b>Methods: Monitoring</b>			
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	10
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	/
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	9
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	/
<b>Ethics and dissemination</b>			
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	13
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	/
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	5,13
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	/
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	10
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	13
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	10
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	/

Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	10
	31b	Authorship eligibility guidelines and any intended use of professional writers	/
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	10
<b>Appendices</b>			
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	/
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	/

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.